PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • These highlights do not include all the information needed to use DUOPA safely and effectively. See full prescribing information for DUOPA.DUOPA (carbidopa and levodopa) enteral suspension Initial U.S. Approval: 1975

    DUOPA- levodopa and carbidopa suspension 
    AbbVie Inc.

    ----------

    HIGHLIGHTS OF PRESCRIBING INFORMATION

    These highlights do not include all the information needed to use DUOPA safely and effectively. See full prescribing information for DUOPA.

    DUOPA (carbidopa and levodopa) enteral suspension
    Initial U.S. Approval: 1975

    RECENT MAJOR CHANGES

    Warnings and Precautions, Gastrointestinal and
    Gastrointestinal Procedure-Related Risks (5.1)
    9/2016

    INDICATIONS AND USAGE

    DUOPA is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease (1)

    DOSAGE AND ADMINISTRATION

    • The maximum recommended daily dose of DUOPA is 2000 mg of levodopa (i.e., one cassette per day) administered over 16 hours (2.1)
    • Prior to initiating DUOPA, convert patients from all forms of levodopa to oral immediate-release carbidopa-levodopa tablets (1:4 ratio) (2.2)
    • Titrate total daily dose based on clinical response for the patient (2.2)
    • Administer DUOPA into the jejunum through a percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) with the CADD®-Legacy 1400 portable infusion pump (2.3)

    DOSAGE FORMS AND STRENGTHS

    Enteral Suspension: 4.63 mg carbidopa and 20 mg levodopa per mL (3)

    CONTRAINDICATIONS

    DUOPA is contraindicated in patients taking nonselective monoamine oxidase (MAO) inhibitors (4)

    WARNINGS AND PRECAUTIONS

    • Gastrointestinal procedure-related complications may result in serious outcomes, such as need for surgery or death (5.1)
    • May cause falling asleep during activities of daily living (5.2)
    • Monitor patients for orthostatic hypotension, especially after starting DUOPA or increasing the dose (5.3)
    • Hallucinations/Psychosis/Confusion: May respond to dose reduction in levodopa (5.4)
    • Impulse Control Disorders: Consider dose reductions or stopping DUOPA (5.5)
    • Monitor patients for depression and suicidality (5.6)
    • Avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal-emergent hyperpyrexia and confusion (5.7)
    • May cause or exacerbate dyskinesia: Consider dose reduction (5.8)
    • Monitor patients for signs and symptoms of peripheral neuropathy (5.9)

    ADVERSE REACTIONS

    Most common adverse reactions for DUOPA (DUOPA incidence at least 7% greater than oral carbidopa-levodopa incidence) were: complication of device insertion, nausea, depression, peripheral edema, hypertension, upper respiratory tract infection, oropharyngeal pain, atelectasis, and incision site erythema. (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    • Selective MAO-B inhibitors: May cause orthostatic hypotension (7.1)
    • Antihypertensive drugs: May cause symptomatic postural hypotension. Dosage adjustment of the antihypertensive drug may be needed (7.2)
    • Dopamine D2 receptor antagonists, isoniazid, iron salts, and high-protein diet may reduce the effectiveness of DUOPA (7.3, 7.4, 7.5)

    USE IN SPECIFIC POPULATIONS

    Pregnancy: Based on animal data, may cause fetal harm (8.1)

    See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

    Revised: 9/2016

    FULL PRESCRIBING INFORMATION: CONTENTS*

    1 INDICATIONS AND USAGE

    2 DOSAGE AND ADMINISTRATION

    2.1 DUOPA Daily Dose

    2.2 Initiation and Titration Instructions

    2.3 Administration Information

    2.4 Discontinuation of DUOPA

    3 DOSAGE FORMS AND STRENGTHS

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Gastrointestinal and Gastrointestinal Procedure-Related Risks

    5.2 Falling Asleep During Activities of Daily Living and Somnolence

    5.3 Orthostatic Hypotension

    5.4 Hallucinations/Psychosis/Confusion

    5.5 Impulse Control/Compulsive Behaviors

    5.6 Depression and Suicidality

    5.7 Withdrawal-Emergent Hyperpyrexia and Confusion

    5.8 Dyskinesia

    5.9 Neuropathy

    5.10 Cardiovascular Ischemic Events

    5.11 Melanoma

    5.12 Laboratory Test Abnormalities

    5.13 Glaucoma

    6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    7 DRUG INTERACTIONS

    7.1 Monoamine Oxidase (MAO) Inhibitors

    7.2 Antihypertensive Drugs

    7.3 Dopamine D2 Receptor Antagonists and Isoniazid

    7.4 Iron Salts

    7.5 High-Protein Diet

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.3 Nursing Mothers

    8.4 Pediatric Use

    8.5 Geriatric Use

    10 OVERDOSAGE

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    14 CLINICAL STUDIES

    16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    16.2 Storage and Handling

    17 PATIENT COUNSELING INFORMATION

    PRODUCT PHOTO

    *
    Sections or subsections omitted from the full prescribing information are not listed.

    FULL PRESCRIBING INFORMATION

    1 INDICATIONS AND USAGE

    DUOPA is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

    2 DOSAGE AND ADMINISTRATION

    2.1 DUOPA Daily Dose

    DUOPA is administered over a 16-hour infusion period. The daily dose is determined by individualized patient titration and composed of:

    • A Morning Dose
    • A Continuous Dose
    • Extra Doses

    The maximum recommended daily dose of DUOPA is 2000 mg of the levodopa component (i.e., one cassette per day) administered over 16 hours. At the end of the daily 16-hour infusion, patients will disconnect the pump from the PEG-J and take their night-time dose of oral immediate-release carbidopa-levodopa tablets.

    Treatment with DUOPA is initiated in 3 steps [see Dosage and Administration (2.2)]:

    1. Conversion of patients to oral immediate-release carbidopa-levodopa tablets in preparation for DUOPA treatment.
    2. Calculation and administration of the DUOPA starting dose (Morning Dose and Continuous Dose) for Day 1.
    3. Titration of the dose as needed based on individual clinical response and tolerability.

    Extra Doses

    DUOPA has an extra dose function that can be used to manage acute “Off” symptoms that are not controlled by the Morning Dose and the Continuous Dose administered over 16 hours. The extra dose function should be set at 1 mL (20 mg of levodopa) when starting DUOPA. If the amount of the extra dose needs to be adjusted, it is typically done in 0.2 mL increments. The extra dose frequency should be limited to one extra dose every 2 hours. Administration of frequent extra doses may cause or worsen dyskinesias.

    Once no further adjustments are required to the DUOPA Morning Dose, Continuous Dose, or Extra Dose, this dosing regimen should be administered daily. Over time, additional changes may be necessary based on the patient’s clinical response and tolerability.

    2.2 Initiation and Titration Instructions

    Prepare for DUOPA Treatment

    Prior to initiating DUOPA, convert patients from all other forms of levodopa to oral immediate-release carbidopa-levodopa tablets (1:4 ratio). Patients should remain on a stable dose of their concomitant medications taken for the treatment of Parkinson's disease before initiation of DUOPA infusion.

    Healthcare providers should ensure patients take their oral Parkinson's disease medications the morning of the PEG-J procedure.

    Determine the DUOPA Starting Dose for Day 1

    The steps for determining the initial DUOPA daily dosing (Morning Dose and Continuous Dose) for Day 1 are outlined below.

    Step 1: Calculate and administer the DUOPA Morning Dose for Day 1
    a. Determine the total amount of levodopa (in milligrams) in the first dose of oral immediate-release carbidopa-levodopa that was taken by the patient on the previous day.
    b. Convert the oral levodopa dose from milligrams to milliliters by multiplying the oral dose by 0.8 and dividing by 20 mg/mL. This calculation will provide the Morning Dose of DUOPA in milliliters.
    c. Add 3 milliliters to the Morning Dose to fill (prime) the intestinal tube to obtain the Total Morning Dose.
    d. The Total Morning Dose is usually administered over 10 to 30 minutes.
    e. Program the pump to deliver the Total Morning Dose.
    Step 2: Calculate and administer the DUOPA Continuous Dose for Day 1
    a. Determine the amount of oral immediate-release levodopa that the patient received from oral immediate-release carbidopa-levodopa doses throughout the previous day (16 waking hours), in milligrams. Do not include the doses of oral immediate-release carbidopa-levodopa taken at night when calculating the levodopa amount.
    b. Subtract the first oral levodopa dose in milligrams taken by the patient on the previous day (determined in Step 1 (a)) from the total oral levodopa dose in milligrams taken over 16 waking hours (determined in Step 2 (a)). Divide the result by 20 mg/mL. This is the dose of DUOPA administered as a Continuous Dose (in mL) over 16 hours.
    c. The hourly infusion rate (mL per hour) is obtained by dividing the Continuous Dose by 16 (hours). This value will be programmed into the pump as the continuous rate.
    d. If persistent or numerous “Off” periods occur during the 16-hour infusion, consider increasing the Continuous Dose or using the Extra Dose function. If dyskinesia or DUOPA-related adverse reactions occur, consider decreasing the Continuous Dose or stopping the infusion until the adverse reactions subside.

    DUOPA Titration

    The daily dose of DUOPA can be titrated as needed, based on the patient’s individual clinical response and tolerability after Day 1 of DUOPA treatment and until a stable daily dose is maintained. Adjustments to concomitant Parkinson’s disease medications may be needed. In the controlled trial, the average number of titration days required to establish a stable Morning and Continuous Dose was 5 days. Additional dose adjustments may be necessary over time based on the patient level of activity and disease progression.

    The recommendations for adjusting the DUOPA Morning and Continuous Doses are provided below.

    Morning Dose Adjustment

    If there was an inadequate clinical response within 1 hour of the Morning Dose on the preceding day, adjust the Morning Dose (excluding the 3 mL to fill the tube) as follows:

    • If the Morning Dose on the preceding day was less than or equal to 6 mL, increase the Morning Dose by 1 mL.
    • If the Morning Dose on the preceding day was greater than 6 mL, increase the Morning Dose by 2 mL.

    If the patient experienced dyskinesias or DUOPA-related adverse reactions within 1 hour of the Morning Dose on the preceding day, decrease the Morning Dose by 1 mL.

    Continuous Dose Adjustment

    Consider increasing the Continuous Dose based on the number and volume of Extra Doses of DUOPA (i.e., total amount of levodopa component) that were needed for the previous day and the patient’s clinical response.

    Consider decreasing the Continuous Dose if the patient experienced troublesome dyskinesia, or other troublesome DUOPA-related adverse reactions on the preceding day:

    • For troublesome adverse reactions lasting for a period of one hour or more, decrease the Continuous Dose by 0.3 mL per hour.
    • For troublesome adverse reactions lasting for two or more periods of one hour or more, decrease the Continuous Dose by 0.6 mL per hour.

    2.3 Administration Information

    • DUOPA should be used at room temperature. Take one DUOPA cassette out of the refrigerator and out of the carton 20 minutes prior to use; failure to use the product at room temperature may result in the patient not receiving the right amount of medication.
    • DUOPA is delivered as a 16-hour infusion through either a naso-jejunal tube for short-term administration or through a PEG-J for long-term administration.
    • The cassettes are for single-use only and should not be used for longer than 16 hours, even if some drug product remains.
    • An opened cassette should not be re-used.
    • The PEG-J should be disconnected from the pump at the end of the daily 16-hour administration period and flushed with room temperature potable water with a syringe.

    Long-term administration of DUOPA requires placement of a PEG-J outer transabdominal tube and inner jejunal tube by percutaneous endoscopic gastrostomy. DUOPA is dispensed from medication cassette reservoirs that are specifically designed to be connected to the CADD®-Legacy 1400 pump.

    Establishment of the transabdominal port should be performed by a gastroenterologist or other healthcare provider experienced in this procedure. See Table 1 for the recommended tubing sets for PEG-J administration.

    For short-term, temporary administration of DUOPA prior to PEG-J tube placement, treatment may be initiated by a naso-jejunal tube with observation of the patient’s clinical response. See Table 2 for the recommended tubing sets for naso-jejunal administration.

    Table 1. Recommended Tubing Sets for Long-Term PEG-J DUOPA Administration
    Product Name Manufacturer
    AbbVie PEG 15 and 20 Fr
    AbbVie J
    AbbVie Inc.
    AbbVie Inc.
    Table 2. Recommended Tubing Sets for Short-Term Naso-Jejunal DUOPA Administration
    Product Name Manufacturer
    AbbVie NJ AbbVie Inc.
    NJFT-10 Wilson-Cook Medical, Inc.
    Kangaroo™ Naso-Jejunal Feeding Tube Covidien
    Kangaroo™ Covidien

    2.4 Discontinuation of DUOPA

    Avoid sudden discontinuation or rapid dose reduction in patients taking DUOPA.

    If patients need to discontinue DUOPA, the dose should be tapered or patients should be switched to oral immediate-release carbidopa-levodopa tablets [see Warnings and Precautions (5.7)].

    When using a PEG-J tube, DUOPA can be discontinued by withdrawing the tube and letting the stoma heal. The removal of the tube should only be performed by a qualified healthcare provider.

    3 DOSAGE FORMS AND STRENGTHS

    Enteral suspension: 4.63 mg carbidopa and 20 mg levodopa per mL in a single-use cassette. Each cassette contains approximately 100 mL of suspension.

    4 CONTRAINDICATIONS

    DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. Hypertension can occur if these drugs are used concurrently [see Drug Interactions (7.1 and 7.2)].

    5 WARNINGS AND PRECAUTIONS

    5.1 Gastrointestinal and Gastrointestinal Procedure-Related Risks

    Because DUOPA is administered using a PEG-J or naso-jejunal tube, gastrointestinal complications can occur.

    These complications include bezoar, ileus, implant site erosion/ulcer, intestinal hemorrhage, intestinal ischemia, intestinal obstruction, intestinal perforation, intussusception, pancreatitis, peritonitis, pneumoperitoneum, and post-operative wound infection. These complications may result in serious outcomes, such as the need for surgery or death.

    Instruct patients to notify their healthcare provider immediately if they experience abdominal pain, prolonged constipation, nausea, vomiting, fever, or melanotic stool [see Patient Counseling Information (17)].

    5.2 Falling Asleep During Activities of Daily Living and Somnolence

    Patients treated with levodopa, a component of DUOPA, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Although many of these patients reported somnolence while on levodopa, some perceived that they had no warning signs (sleep attack), such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events have been reported more than one year after initiation of treatment.

    Falling asleep while engaged in activities of daily living usually occurs in patients experiencing preexisting somnolence, although patients may not give such a history. For this reason, prescribers should reassess patients for drowsiness or sleepiness in DUOPA-treated patients, especially since some of the events occur well after the start of treatment. Prescribers should be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities. Patients who have already experienced somnolence or an episode of sudden sleep onset should not participate in these activities while taking DUOPA.

    Before initiating treatment with DUOPA, advise patients about the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with DUOPA such as the use of concomitant sedating medications or the presence of sleep disorders. Consider discontinuing DUOPA in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating). If DUOPA is continued, they should be advised to avoid driving and other potentially dangerous activities that might result in harm if the patient becomes somnolent.

    5.3 Orthostatic Hypotension

    DUOPA-treated patients were more likely to experience a decline in orthostatic blood pressure than patients treated with oral immediate-release carbidopa-levodopa in the controlled clinical study. Orthostatic systolic hypotension (≥30 mm Hg decrease) occurred in 73% of DUOPA-treated patients compared to 68% of patients treated with oral immediate-release carbidopa-levodopa in the controlled clinical study. Orthostatic diastolic hypotension (≥20 mm Hg decrease) occurred in 70% of DUOPA-treated patients compared to 62% of patients treated with oral immediate-release carbidopa-levodopa. Inform patients about the risk for hypotension and syncope. Monitor patients for orthostatic hypotension, especially after starting DUOPA or increasing the dose.

    5.4 Hallucinations/Psychosis/Confusion

    There is an increased risk for hallucinations and psychosis in patients taking DUOPA. In the controlled clinical trial, hallucinations occurred in 5% of DUOPA-treated patients compared to 3% of patients treated with oral immediate-release carbidopa-levodopa. Confusion occurred in 8% of DUOPA-treated patients compared to 3% of patients treated with oral immediate-release carbidopa-levodopa, and psychotic disorder occurred in 5% of DUOPA-treated patients compared to 3% of patients treated with oral immediate-release carbidopa-levodopa.

    Hallucinations associated with levodopa may present shortly after the initiation of therapy and may be responsive to dose reduction in levodopa. Confusion, insomnia, and excessive dreaming may accompany hallucinations. Abnormal thinking and behavior may present with one or more symptoms, including paranoid ideation, delusions, hallucinations, confusion, psychosis, disorientation, aggressive behavior, agitation, and delirium.

    Because of the risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with DUOPA. In addition, medications that antagonize the effects of dopamine used to treat psychosis may exacerbate the symptoms of Parkinson’s disease and may decrease the effectiveness of DUOPA [see Drug Interactions (7.3)].

    5.5 Impulse Control/Compulsive Behaviors

    Patients may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including DUOPA, that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued.

    Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with DUOPA. Consider reducing the dose or discontinuing DUOPA if a patient develops such urges.

    5.6 Depression and Suicidality

    In the controlled clinical trial, 11% of DUOPA-treated patients developed depression compared to 3% of oral immediate-release carbidopa-levodopa-treated patients.

    Monitor patients for the development of depression and concomitant suicidal tendencies.

    5.7 Withdrawal-Emergent Hyperpyrexia and Confusion

    A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Avoid sudden discontinuation or rapid dose reduction in patients taking DUOPA. If DUOPA is discontinued, the dose should be tapered to reduce the risk of hyperpyrexia and confusion [see Dosage and Administration (2.4)].

    5.8 Dyskinesia

    DUOPA may cause or exacerbate dyskinesias. In the controlled clinical trial, dyskinesia occurred in 14% of DUOPA-treated patients compared to 12% of patients treated with oral immediate-release carbidopa-levodopa. The occurrence of dyskinesias may require a dosage reduction of DUOPA or other medications used to treat Parkinson’s disease.

    5.9 Neuropathy

    In clinical studies, 19 of 412 (5%) patients treated with DUOPA developed a generalized polyneuropathy. The onset of neuropathy could be determined in 13 of 19 patients. Most cases (12/19) were classified as subacute or chronic in onset. The neuropathy was most often characterized as sensory or sensorimotor. Electrodiagnostic testing performed in 16 patients was most often (15/16) consistent with an axonal polyneuropathy, and one patient was classified as having a demyelinating neuropathy. There was insufficient information to determine the potential role of vitamin deficiencies in the etiology of neuropathy associated with DUOPA.

    Patients should have clinical assessments for the signs and symptoms of peripheral neuropathy before starting DUOPA. Monitor patients periodically for signs of neuropathy after starting DUOPA, especially in patients with pre-existing neuropathy and in patients taking medications or those who have medical conditions that are also associated with neuropathy.

    5.10 Cardiovascular Ischemic Events

    In clinical studies, myocardial infarction and arrhythmia were reported in patients taking carbidopa-levodopa. Ask patients about symptoms of ischemic heart disease and arrhythmia, especially those with a history of myocardial infarction or cardiac arrhythmias.

    5.11 Melanoma

    Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2 to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson’s disease or other factors, such as drugs used to treat Parkinson’s disease, is unclear. In the clinical studies, 2 of 416 (0.5%) DUOPA-treated patients developed melanoma.

    Appropriately qualified health care providers (e.g., dermatologists) should perform periodic skin examinations to monitor for melanoma in patients receiving DUOPA.

    5.12 Laboratory Test Abnormalities

    DUOPA may increase the risk for elevated (above the upper limit of normal for the reference range) blood urea nitrogen (BUN) and creatine phosphokinase (CPK). In the controlled clinical trial, the shift from a low or normal value at baseline to an increased BUN value was greater for DUOPA-treated patients (13%) than for patients treated with oral immediate-release carbidopa-levodopa (4%). The shift from a low or normal value at baseline to an increased CPK value was greater for DUOPA-treated patients (17%) than for patients treated with oral immediate-release carbidopa-levodopa (7%). The incidence of patients with a markedly increased BUN (≥10 mmol/L; ≥28 mg/dL) was greater for patients treated with DUOPA (11%) than that for patients treated with oral immediate-release carbidopa-levodopa (0%). The incidence of patients with an increased CPK (>3 times the upper limit of normal) was greater for patients treated with DUOPA (9%) than that for patients treated with oral immediate-release carbidopa-levodopa (0%).

    Patients taking levodopa or carbidopa-levodopa may have increased levels of catecholamines and their metabolites in plasma and urine giving false positive results suggesting the diagnosis of pheochromocytoma in patients on levodopa and carbidopa-levodopa.

    5.13 Glaucoma

    Carbidopa-levodopa may cause increased intraocular pressure in patients with glaucoma. Monitor intraocular pressure in patients with glaucoma after starting DUOPA.

    6 ADVERSE REACTIONS

    The following serious adverse reactions are discussed below and elsewhere in labeling:

    • Gastrointestinal and Gastrointestinal Procedure-Related Risks [see Warnings and Precautions (5.1)]
    • Falling Asleep During Activities of Daily Living and Somnolence [see Warnings and Precautions (5.2)]
    • Orthostatic Hypotension [see Warnings and Precautions (5.3)]
    • Hallucinations/Psychosis/Confusion [see Warnings and Precautions (5.4)]
    • Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.5)]
    • Depression and Suicidality [see Warnings and Precautions (5.6)]
    • Withdrawal-Emergent Hyperpyrexia and Confusion [see Warnings and Precautions (5.7)]
    • Dyskinesia [see Warnings and Precautions (5.8)]
    • Neuropathy [see Warnings and Precautions (5.9)]
    • Cardiovascular Ischemic Events [see Warnings and Precautions (5.10)]
    • Melanoma [see Warnings and Precautions (5.11)]
    • Laboratory Test Abnormalities [see Warnings and Precautions (5.12)]
    • Glaucoma [see Warnings and Precautions (5.13)]

    6.1 Clinical Trials Experience

    Because clinical studies are run under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In clinical studies, 416 patients with advanced Parkinson’s disease received DUOPA. 338 patients were treated with DUOPA for more than 1 year, 233 patients were treated with DUOPA for more than 2 years, and 162 patients were treated with DUOPA for more than 3 years.

    In a 12-week, active-controlled clinical trial (Study 1), a total of 71 patients with advanced Parkinson’s disease were enrolled and had a PEG-J procedure. Of these, 37 patients received DUOPA and 34 received oral immediate-release carbidopa-levodopa.

    The most common adverse reactions for DUOPA (incidence at least 7% greater than oral immediate-release carbidopa-levodopa) were: complication of device insertion, nausea, depression, peripheral edema, hypertension, upper respiratory tract infection, oropharyngeal pain, atelectasis, and incision site erythema.

    Table 3 lists the incidence of adverse reactions occurring in the DUOPA-treated group (requiring at least 2 patients in this group) in Study 1 when the incidence was numerically greater than that for oral immediate-release carbidopa-levodopa.

    Table 3. Adverse Reactions in Study 1 for DUOPA in Patients with Advanced Parkinson’s disease
    Preferred Term DUOPA
    (n = 37)
    %
    Oral immediate-release carbidopa-levodopaa
    (n = 34)
    %
    Complication of device insertion 57 44
    Nausea 30 21
    Constipation 22 21
    Incision site erythema 19 12
    Dyskinesia 14 12
    Depression 11 3
    Post procedural discharge 11 9
    Peripheral edema 8 0
    Hypertension 8 0
    Upper respiratory tract infection 8 0
    Oropharyngeal pain 8 0
    Atelectasis 8 0
    Confusional state 8 3
    Anxiety 8 3
    Dizziness 8 6
    Hiatal hernia 8 6
    Postoperative ileus 5 0
    Sleep disorder 5 0
    Pyrexia 5 0
    Excessive granulation tissue 5 0
    Rash 5 0
    Bacteriuria 5 0
    White blood cells urine positive 5 0
    Hallucination 5 3
    Psychotic disorder 5 3
    Diarrhea 5 3
    Dyspepsia 5 3
    aAll patients in the clinical trial regardless of treatment arm received a PEG-J.

    Procedure and Device- Related Adverse Reactions

    The most common adverse reactions associated with complications due to naso-jejunal (NJ) insertion were: oropharyngeal pain, abdominal distention, abdominal pain, abdominal discomfort, pain, throat irritation, gastrointestinal injury, esophageal hemorrhage, anxiety, dysphagia, and vomiting.

    The most common adverse reactions associated with complications due to PEG-J insertion were: abdominal pain, abdominal discomfort, abdominal distension, flatulence, or pneumoperitoneum.

    Additional adverse reactions that were co-reported with complication of naso-jejunal and PEG-J insertion included upper abdominal pain, duodenal ulcer, duodenal ulcer hemorrhage, erosive duodenitis, erosive gastritis, gastrointestinal hemorrhage, intussusception, peritonitis, post-operative abscess, and small intestine ulcer.

    7 DRUG INTERACTIONS

    7.1 Monoamine Oxidase (MAO) Inhibitors

    The use of nonselective MAO inhibitors with DUOPA is contraindicated [see Contraindications (4)]. Discontinue use of any nonselective MAO inhibitors at least two weeks prior to initiating DUOPA.

    The use of selective MAO-B inhibitors (e.g., rasagiline and selegiline) with DUOPA may be associated with orthostatic hypotension. Monitor patients who are taking these drugs.

    7.2 Antihypertensive Drugs

    The concurrent use of DUOPA with antihypertensive medications can cause symptomatic postural hypotension. A dose reduction of the antihypertensive medication may be needed after starting or increasing the dose of DUOPA.

    7.3 Dopamine D2 Receptor Antagonists and Isoniazid

    Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide, papaverine) and isoniazid may reduce the effectiveness of levodopa. Monitor patients for worsening Parkinson’s symptoms.

    7.4 Iron Salts

    Iron salts or multi-vitamins containing iron salts can form chelates with levodopa, carbidopa, and can cause a reduction in the bioavailability of DUOPA. If iron salts or multi-vitamins containing iron salts are co-administered with DUOPA, monitor patients for worsening Parkinson’s symptoms.

    7.5 High-Protein Diet

    Because levodopa competes with certain amino acids for transport across the gut wall, the absorption of levodopa may be decreased in patients on a high-protein diet. Advise patients that a high-protein diet may reduce the effectiveness of DUOPA.

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category C.

    There are no adequate or well-controlled studies in pregnant women. It has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. In animal studies, carbidopa-levodopa has been shown to be developmentally toxic (including teratogenic effects) at clinically relevant doses. DUOPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    When administered to pregnant rabbits throughout organogenesis, carbidopa-levodopa caused both visceral and skeletal malformations in fetuses at all doses and ratios of carbidopa-levodopa tested. No teratogenic effects were observed when carbidopa-levodopa was administered to pregnant mice throughout organogenesis.

    There was a decrease in the number of live pups delivered by rats receiving carbidopa-levodopa during organogenesis.

    8.3 Nursing Mothers

    Carbidopa is excreted in rat milk. In a study of one nursing mother with Parkinson’s disease, excretion of levodopa in human milk was reported. Caution should be exercised when DUOPA is administered to a nursing woman.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    In the controlled clinical trial, 49% of patients were 65 years and older, and 8% were 75 years and older. In patients 65 years and older, there was an increased risk for elevation of BUN and CPK (above the upper limit of the normal reference range for these laboratory analytes) during treatment with DUOPA compared to the risk for patients less than 65 years.

    10 OVERDOSAGE

    Management of acute overdosage with DUOPA is the same as management of acute overdosage with levodopa. Pyridoxine is not effective in reversing the actions of oral immediate-release carbidopa-levodopa.

    In the event of an overdosage with DUOPA, the infusion should be stopped and the pump disconnected immediately. Administer intravenous fluids and maintain an adequate airway. Patients should receive electrocardiographic monitoring for arrhythmias and hypotension.

    11 DESCRIPTION

    DUOPA is a combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an aromatic amino acid.

    Carbidopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.2. It is designated chemically as (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O, and its structural formula is:

    carbidopa chem structure

    The content of carbidopa in DUOPA is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3. The 4.63 mg/mL of anhydrous carbidopa is equivalent to 5.0 mg/mL of carbidopa.

    Levodopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (2S)-2-Amino-3-(3,4-dihydroxyphenyl) propanoic acid. Its empirical formula is C9H11NO4, and its structural formula is:

    levodopa chem structure

    The inactive ingredients in DUOPA are carmellose sodium and purified water.

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Carbidopa

    When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain.

    Levodopa

    Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats the symptoms of Parkinson's disease.

    12.2 Pharmacodynamics

    Because its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more levodopa available to the brain. The addition of carbidopa to levodopa reduces the peripheral effects (e.g., nausea and vomiting) due to decarboxylation of levodopa; however, carbidopa does not decrease the adverse reactions due to the central effects of levodopa.

    12.3 Pharmacokinetics

    The pharmacokinetics of carbidopa and levodopa with 16-hour intrajejunal infusion of DUOPA was evaluated in 18 patients with advanced Parkinson's disease who had been on DUOPA therapy for 30 days or longer. Patients remained on their individualized DUOPA doses.

    The plasma concentrations versus time profile for levodopa with DUOPA 16-hour intrajejunal infusion is presented in Figure 1.

    levodopa plasma conc over time

    Figure 1. Plasma Concentrations (mean ± standard deviation) versus Time Profile of Levodopa with DUOPA (levodopa, 1580 ± 403 mg; carbidopa, 366 ± 92 mg) 16-Hour Infusion

    Absorption and Bioavailability

    Following initiation of the 16-hour intrajejunal infusion of DUOPA, peak plasma levels of levodopa is reached at 2.5 hours. The absorption of levodopa may be decreased in patients on a high-protein diet because levodopa competes with certain amino acids for transport across the gut wall. The gastric emptying rate does not influence the absorption of DUOPA since it is administered by continuous intestinal infusion. In a cross-study population pharmacokinetic analysis, DUOPA had comparable bioavailability to the oral immediate-release carbidopa-levodopa (25/100 mg) tablets (over-encapsulated tablets). The estimated bioavailability for levodopa from DUOPA relative to oral immediate-release carbidopa-levodopa tablets was 97% (95% confidence interval; 95% to 98%).

    In the controlled clinical trial, the intra-subject variability in carbidopa and levodopa plasma concentrations were lower for patients treated with DUOPA (N=33, 25% and 21%, respectively) than in patients treated with oral immediate-release carbidopa-levodopa (25/100 mg) tablets (N=28, 39% and 67%, respectively).

    Distribution

    Carbidopa is approximately 36% bound to plasma proteins. Levodopa is approximately 10-30% bound to plasma proteins.

    Metabolism and Elimination

    Carbidopa

    Carbidopa is metabolized to two main metabolites (α-methyl-3-methoxy-4-hydroxyphenylpropionic acid and α-methyl-3,4-dihydroxyphenylpropionic acid). These 2 metabolites are primarily eliminated in the urine unchanged or as glucuronide conjugates. Unchanged carbidopa accounts for 30% of the total urinary excretion. The elimination half-life of carbidopa is approximately 2 hours.

    Levodopa

    Levodopa is mainly eliminated via metabolism by the aromatic amino acid decarboxylase (AAAD) and the catechol-O-methyl-transferase (COMT) enzymes. Other routes of metabolism are transamination and oxidation. The decarboxylation of levodopa to dopamine by AAAD is the major enzymatic pathway when no enzyme inhibitor is co-administered. O-methylation of levodopa by COMT forms 3-O-methyldopa. When administered with carbidopa, the elimination half-life of levodopa is approximately 1.5 hours (see Figure 1).

    Drug Interaction Studies

    COMT Inhibitors

    Systemic exposure of levodopa is expected to increase in the presence of entacapone.

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    In rat, oral administration of carbidopa-levodopa for two years resulted in no evidence of carcinogenicity. DUOPA contains hydrazine, a degradation product of carbidopa. In published studies, hydrazine has been demonstrated to be carcinogenic in multiple animal species. Increases in liver (adenoma, carcinoma) and lung (adenoma, adenocarcinoma) tumors have been reported with oral administration of hydrazine in mouse, rat, and hamster.

    Mutagenesis

    Carbidopa was positive in the in vitro Ames test, in the presence and absence of metabolic activation, and the in vitro mouse lymphoma tk assay in the absence of metabolic activation but was negative in the in vivo mouse micronucleus assay.

    In published studies, hydrazine was reported to be positive in in vitro genotoxicity (Ames, chromosomal aberration in mammalian cells, and mouse lymphoma tk) assays and in the in vivo mouse micronucleus assay.

    Impairment of Fertility

    In reproduction studies, no effects on fertility were observed in rats receiving carbidopa -levodopa.

    14 CLINICAL STUDIES

    The efficacy of DUOPA was established in a randomized, double-blind, double-dummy, active-controlled, parallel group, 12-week study (Study 1) in patients with advanced Parkinson's disease who were levodopa-responsive and had persistent motor fluctuations while on treatment with oral immediate-release carbidopa-levodopa and other Parkinson's disease medications.

    Patients were eligible for participation in the studies if they were experiencing 3 hours or more of “Off” time on their current Parkinson's disease drug treatment and they demonstrated a clear responsiveness to treatment with levodopa. Seventy-one (71) patients enrolled in the study and 66 patients completed the treatment (3 patients discontinued treatment because of adverse reactions, 1 patient for lack of effect, and 1 patient for non-compliance).

    Patients enrolled in this study had a mean age of 64 years and disease duration of 11 years. Most patients (89%) were taking at least one concomitant medication for Parkinson’s disease (e.g., dopaminergic agonist, COMT-inhibitor, MAO-B inhibitor) in addition to oral immediate-release carbidopa-levodopa. Thirty nine percent of patients were taking two or more of such concomitant medications.

    Patients were randomized to either DUOPA and placebo capsules or placebo suspension and oral immediate-release carbidopa-levodopa 25/100 mg capsules. Patients in both treatment arms had a PEG-J device placement. DUOPA or placebo-suspension was infused over 16 hours daily through a PEG-J tube via the CADD®-Legacy 1400 model ambulatory infusion pump. The mean daily levodopa dose was 1117 mg/day in the DUOPA group and 1351 mg/day in the oral immediate-release carbidopa-levodopa group.

    The clinical outcome measure in Study 1 was the mean change from baseline to Week 12 in the total daily mean “Off” time, based on a Parkinson's disease diary. The "Off" time was normalized to a 16-hour awake period, based on a typical person's waking day and the daily infusion duration of 16 hours. The mean score decrease (i.e., improvement) in “Off” time from baseline to Week 12 for DUOPA was significantly greater (p=0.0015) than for oral immediate-release carbidopa-levodopa. Additionally, the mean score increase (i.e., improvement) in “On” time without troublesome dyskinesia from baseline to Week 12 was significantly greater (p=0.0059) for DUOPA than for oral immediate-release carbidopa-levodopa. The treatment difference (DUOPA – oral immediate release carbidopa-levodopa) for decrease in “Off” time was approximately 1.9 hours and the treatment difference for the increase in “On” time without troublesome dyskinesia was approximately 1.9 hours. Results of Study 1 are shown in Table 4.

    Table 4. Change from Baseline to Week 12 in "Off" Time and in "On" Time Without Troublesome Dyskinesia in Patients with Advanced Parkinson’s Disease
    Treatment Group Baseline
    (hours)
    LS Mean Change from Baseline at Week 12
    (hours)
    "Off" time
      Oral immediate-release carbidopa-levodopa 6.9 -2.1
       DUOPA 6.3 -4.0*
    "On" time without troublesome dyskinesia
      Oral immediate-release carbidopa-levodopa 8.0 2.2
       DUOPA 8.7 4.1*

    LS Mean Change from Baseline based on Analysis of Covariance (ANCOVA).

    *=Statistically Significant.

    Figure 2 shows results over time according to treatment for the efficacy variable (change from baseline in “Off” time) that served as the clinical outcome measure at the end of the trial at 12 weeks.

    Fig 2 - change in off time

    Figure 2. Change in “Off” Time Over 12 Weeks.

    16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Single-use cassettes containing 4.63 mg carbidopa (as 5 mg of the monohydrate) and 20 mg levodopa per mL of enteral suspension. Each cassette contains approximately 100 mL of suspension.

    Carton of 7 DUOPA cassettes: NDC 0074-3012-07

    16.2 Storage and Handling

    Store in freezer at -20oC (-4oF). Thaw in refrigerator at 2oC to 8oC (36oF to 46oF) prior to dispensing. Cassettes should be protected from light and kept in the carton prior to use.

    Thawing instructions for pharmacies

    • Assign a 12 week “Use By” date based on the time the cartons are put into the refrigerator to thaw.
    • Fully thaw DUOPA in the refrigerator prior to dispensing.
    • In order to ensure controlled thawing of DUOPA, take the cartons containing the seven individual cassettes out of the transport box and separate the cartons from each other.
    • Thawing may take up to 96 hours when the cartons are taken out of the transport box.
    • Once the product has thawed, the individual cartons may be packed in a closer configuration within the refrigerator.

    17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

    Administration Information

    Ask patients if they have had any previous surgery in the upper part of their abdomen that may lead to difficulty in performing the gastrostomy or jejunostomy [see Dosage and Administration (2.3)].

    Advise patients that foods that are high in protein may reduce the effectiveness of DUOPA [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].

    Interruption of DUOPA Infusion

    If the patient anticipates disconnecting the pump for a short period of time (less than 2 hours such as to swim, shower, or short medical procedure), no supplemental oral medication is needed, but the patient may be advised to take an extra-dose of DUOPA before disconnecting. Instruct the patient to stop the continuous rate, turn off the pump, clamp the cassette tube, disconnect the tubing, and replace the red cap on the cassette tube. The DUOPA cassette can remain attached to the pump until the tubing is reconnected. Refer the patient to the Patient Instructions for Use for additional information (i.e., changing the DUOPA Cassette: disconnecting Steps 1-5 and reconnecting Steps 10-16).

    Advise the patient to contact their healthcare provider and to take oral carbidopa-levodopa until the patient is able to resume DUOPA infusion, if the patient will have prolonged interruption of therapy lasting more than 2 hours [see Dosage and Administration (2.4)].

    Gastrointestinal and Gastrointestinal Procedure-Related Risks

    Inform patients of the gastrointestinal procedure-related risks including bezoar, ileus, implant site erosion/ulcer, intestinal hemorrhage, intestinal ischemia, intestinal obstruction, intestinal perforation, intussusception, pancreatitis, peritonitis, pneumoperitoneum, post-operative wound infection and sepsis. Advise patients of the symptoms of the above listed complications and instruct them to contact their healthcare provider if they experience any of these symptoms [see Warnings and Precautions (5.1)].

    Falling Asleep during Activities of Daily Living and Somnolence

    Alert patients to the potential sedating effects caused by DUOPA, including somnolence and the possibility of falling asleep while engaged in activities of daily living. Because somnolence is a common adverse reaction with potentially serious consequences, patients should not drive a car, operate machinery, or engage in other potentially dangerous activities until they have gained sufficient experience with DUOPA to gauge whether or not it affects their mental and/or motor performance adversely. Advise patients that if increased somnolence or episodes of falling asleep during activities of daily living (e.g., conversations, eating, driving a motor vehicle, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician.

    Advise patients of possible additive effects when patients are taking other sedating medications, alcohol, or other central nervous system depressants (e.g., benzodiazepines, antipsychotics, antidepressants, etc.) in combination with DUOPA or when taking a concomitant medication that increases plasma levels of levodopa [see Warnings and Precautions (5.2)].

    Orthostatic Hypotension

    Advise patients that they may experience syncope and may develop hypotension with or without symptoms such as dizziness, nausea, syncope, and sometimes sweating while taking DUOPA. Accordingly, caution patients against standing rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with DUOPA [see Warnings and Precautions (5.3)].

    Hallucinations/Psychosis/Confusion

    Inform patients that they may experience hallucinations (unreal visions, sounds, or sensations) and other symptoms of psychosis can occur while taking DUOPA. Tell patients to report hallucinations, abnormal thinking, psychotic behavior or confusion to their healthcare provider promptly should they develop [see Warnings and Precautions (5.4)].

    Impulse Control/Compulsive Behaviors

    Advise patients that they may experience impulse control and/or compulsive behaviors while taking DUOPA. Advise patients to inform their physician or healthcare provider if they develop new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with DUOPA [see Warnings and Precautions (5.5)].

    Depression and Suicidality

    Inform patients that they may develop depression or experience worsening of depression while taking DUOPA. Instruct patients to contact their healthcare provider if they experience depression, worsening of depression, or suicidal thoughts [see Warnings and Precautions (5.6)].

    Withdrawal-Emergent Hyperpyrexia and Confusion

    Advise patients to contact their healthcare provider before stopping DUOPA. Tell patients to inform their healthcare provider if they develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness [see Warnings and Precautions (5.7)].

    Dyskinesia

    Inform patients that DUOPA may cause or exacerbate pre-existing dyskinesias [see Warnings and Precautions (5.8)].

    Neuropathy

    Inform patients that neuropathy may develop or they may experience worsening neuropathy on DUOPA, and to contact their healthcare provider if they develop any symptoms or features suggesting neuropathy [see Warnings and Precautions (5.9)].

    Melanoma

    Advise patients with Parkinson’s disease that they have a higher risk of developing melanoma. Advise patients to have their skin examined on a regular basis by a qualified healthcare provider (e.g., dermatologist) when using DUOPA [see Warnings and Precautions (5.11)].

    Nursing Mothers

    Because of the possibility that carbidopa or levodopa may be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [see Use in Specific Populations (8.3)].


    Manufactured by AbbVie Inc., North Chicago, IL 60064, USA
    or by Fresenius Kabi Norge AS, 1788 Halden, Norway
    For AbbVie Inc.
    North Chicago, IL 60064, USA

    03-B402 September 2016

    MEDICATION GUIDE

    DUOPA (Do-oh-pa)

    (carbidopa and levodopa) enteral suspension


    Read this Medication Guide before you start using DUOPA and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

    What is the most important information I should know about DUOPA?

    DUOPA can cause serious side effects, including:

    • Stomach and intestine (gastrointestinal) problems and problems from the procedure you will need to have to receive DUOPA (gastrointestinal procedure-related problems).

      Some of these problems may require surgery and may lead to death.

      • a blockage of your stomach or intestines (bezoar)
      • stopping movement through intestines (ileus)
      • drainage, redness, swelling, pain, feeling of warmth around the small hole in your stomach wall (stoma)
      • bleeding from stomach ulcers or your intestines
      • inflammation of your pancreas (pancreatitis)
      • air or gas in your abdominal cavity
      • skin infection around the intestinal tube, infection in your blood or abdominal cavity may occur, after surgery
      • stomach pain, nausea or vomiting
    • Tell your healthcare provider right away if you have any of the following symptoms of stomach and intestine problems and gastrointestinal procedure-related problems:
      • stomach (abdominal) pain
      • constipation that does not go away
      • nausea or vomiting
      • fever
      • blood in your stool or a dark tarry stool (melanotic stool)

    You will need to have a procedure to make a small hole (called a “stoma”) in your stomach wall to place a gastro-jejunostomy tube (called a PEG-J tube) in an area of your small intestine called the jejunum. DUOPA is delivered directly to your small intestine through this tube. Your healthcare provider will talk to you about the stoma procedure. Before the stoma procedure, tell your healthcare provider if you have ever had a surgery or problems with your stomach.

    Talk to your healthcare provider about what you need to do to care for your stoma. After the procedure, you and your healthcare provider will need to regularly check the stoma for any signs of infection.

    If your PEG-J tube becomes kinked, knotted, or blocked this may cause you to have worsening of your Parkinson’s symptoms or recurring movement problems (motor fluctuations). Call your healthcare provider if your Parkinson’s symptoms get worse or you have slow movement while you are treated with DUOPA.

    What is DUOPA?

    DUOPA is a prescription medicine used for treatment of advanced Parkinson's disease. DUOPA contains 2 medicines, carbidopa and levodopa.

    DUOPA should not be given to children (younger than 18 years).

    Who should not use DUOPA?

    Do not use DUOPA if you:

    • take a medicine called a nonselective Monoamine Oxidase (MAO) Inhibitor (such as phenelzine or tranylcypromine) or have taken a nonselective MAO Inhibitor within the last 14 days.
      Ask your healthcare provider or pharmacist if you are not sure if you take an MAO Inhibitor.

    What should I tell my healthcare provider before using DUOPA?

    Before you use DUOPA, tell your healthcare provider if you:

    • have or have had stomach ulcers or stomach surgery
    • have low blood pressure (hypotension) or if you feel dizzy or faint, especially when getting up from sitting or lying down
    • have had problems with fainting (syncope)
    • feel sleepy or have fallen asleep suddenly during the day
    • have or have had depression (feelings of hopelessness or sadness) or any mental problems
    • drink alcohol. Alcohol can increase the chance that DUOPA will make you feel sleepy or fall asleep when you should be awake
    • have trouble controlling your muscles (dyskinesia)
    • have nerve problems (peripheral neuropathy)
    • have or have had heart problems, an abnormal heart rate or have had a heart attack in the past
    • have or have had a type of skin cancer called melanoma
    • have or have had high blood pressure (hypertension)
    • have eye problems that cause increased pressure in your eye (glaucoma)
    • have a history of attacks of suddenly falling asleep and without warning
    • have any other medical conditions
    • are pregnant or planning to become pregnant. It is not known if DUOPA will harm your unborn baby
    • are breastfeeding or plan to breastfeed. DUOPA can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take DUOPA

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements.

    Using DUOPA with certain other medicines may affect each other and cause serious side effects.

    Especially tell your healthcare provider if you take:

    • medicines used to treat high blood pressure (hypertension)
    • medicines used to treat depression called nonselective Monoamine Oxidase (MAO) Inhibitor (such as phenelzine or tranylcypromine) or have taken one within the last 14 days
    • dopamine D2 receptor antagonists (antipsychotics or metoclopramide), and isoniazid
    • iron or multivitamins with iron

    Eating high protein foods may affect how DUOPA works. Tell your healthcare provider if you change your diet.

    Ask your healthcare provider or pharmacist for a list of these medicines or foods if you are not sure.

    Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    How should I use DUOPA?

    • Use DUOPA exactly as your healthcare provider tells you to use it.
    • Your healthcare provider should show you how to use DUOPA before you use it for the first time. Ask your healthcare provider or pharmacist if you have any questions.
    • Your prescribed dose of DUOPA will be programmed into your pump by a healthcare provider and should only be changed by your healthcare provider or while you are with your healthcare provider.
    • Do not stop using DUOPA or change your dose unless you are told to do so by your healthcare provider. Tell your healthcare provider if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.
    • Keep a supply of oral carbidopa-levodopa immediate release (IR) tablets with you in case you are unable to give your DUOPA infusion.
    • DUOPA is given continuously over 16 hours through a tube that is put into your stomach called a PEG-J. A small pump (CADD-Legacy 1400) is used to move DUOPA from the medication cassette through your PEG-J tube.
    • Your DUOPA dose has three parts:
      • a morning dose
      • a continuous dose
      • extra doses
    • DUOPA can also be given for a short time (short-term) through a tube put into your nose called a naso-jejunal (NJ) tube.
    • The CADD-Legacy 1400 portable infusion pump should be used to give DUOPA through your PEG-J tube. See the Instructions for Use that comes with your CADD-Legacy 1400 portable infusion pump for complete instructions on how to use the pump.
    • DUOPA comes in a small plastic container (cassette) that you connect to the pump to get your medicine.
      • Each cassette can only be used 1 time. An opened cassette should not be reused.
      • The cassette should not be used for longer than 16 hours.
      • The cassette should be thrown away at the end of the infusion, even if there is some medicine still in the cassette.
    • Disconnect the pump from your PEG-J tube after the 16 hour dosing time is finished. Use a syringe filled with room temperature water to flush your PEG-J tube. See the “Instructions for Use” for more information about how to flush your PEG-J tube with a syringe.
    • After your daily DUOPA infusion, you should take your usual night-time dose of oral carbidopa-levodopa tablets as prescribed.
    • If you stop your DUOPA infusion for more than 2 hours during your 16 hour dosing time for any reason, call your healthcare provider and take oral carbidopa-levodopa as prescribed until you are able to restart your DUOPA infusion.
    • If you stop your DUOPA infusion for less than 2 hours, you do not need to take oral carbidopa-levodopa, but your healthcare provider may tell you to take an extra dose of DUOPA.

    What should I avoid while using DUOPA?

    • Do not drive, operate machinery, or do other activities until you know how DUOPA affects you. Sleepiness and falling asleep suddenly caused by DUOPA can happen as late as 1 year after you start your treatment.

    What are the possible side effects of DUOPA?

    DUOPA may cause serious side effects, including:

    • See “What is the most important information I should know about DUOPA?”
    • Falling asleep during normal daily activities. DUOPA may cause you to fall asleep while you are doing daily activities such as driving, talking with other people, or eating.
      • You could fall asleep without any warning.
      • Some people using DUOPA have had car accidents because they fell asleep while driving.
        Do not drive or operate machinery until you are sure how DUOPA affects you.
        Tell your healthcare provider if you take other medicines that can make you sleepy such as sleep medicines, antidepressants, or antipsychotics.
    • Low blood pressure when you sit or stand up quickly. After you have been sitting or lying down, stand up slowly until you know how DUOPA affects you. This may help reduce the following symptoms while you are using DUOPA:
      • dizziness
      • nausea
      • sweating
      • fainting
    • Seeing things that are not there, hearing sounds or feeling sensations that are not real (hallucinations). Hallucinations can happen in people who use DUOPA. Tell your healthcare provider if you have hallucinations.
    • Unusual urges. Some people taking certain medicines to treat Parkinson’s disease, including DUOPA, have reported problems, such as gambling, compulsive eating, compulsive shopping, and increased sex drive.
      If you or your family members notice that you are having unusual urges or behaviors, talk to your healthcare provider.
    • Depression and suicide. DUOPA can cause depression or make your depression worse. Pay close attention to sudden changes in your mood, behavior, thoughts, or feelings. Call your healthcare provider right away if you feel depressed or have thoughts of suicide.
    • Uncontrolled sudden movements (dyskinesia). If you have new dyskinesia, or your dyskinesia gets worse, tell your healthcare provider. This may be a sign that your dose of DUOPA or other medicines to control your Parkinson’s disease may need to be adjusted.
    • Progressive weakness or numbness or loss of sensation in the fingers or feet (neuropathy).
    • Heart attack or other heart problems. Tell your healthcare provider if you have experienced increased blood pressure, a fast or irregular heartbeat or chest pain.
    • Skin cancer (melanoma). Parkinson's disease may be associated with a higher chance of having melanoma than people who do not have Parkinson’s disease. It is not known if the chance of having melanoma is higher because of the medicines used to treat Parkinson’s disease, like DUOPA, or from the Parkinson’s disease. People who use DUOPA should have their skin checked regularly for melanoma by a qualified healthcare professional.
    • Abnormal blood tests. DUOPA may cause changes in certain blood tests, especially certain hormone and kidney function blood tests.
    • Worsening of the increased pressure in your eyes (glaucoma). The pressure in your eyes should be checked after starting DUOPA.
    • The most common side effects of DUOPA include:
      • swelling of legs and feet
      • nausea
      • high blood pressure (hypertension)
      • depression
      • mouth and throat pain

    Call your healthcare provider or get medical care right away if you have any of the above symptoms. Your healthcare provider will tell you if you should stop treatment with DUOPA and if needed, tell you how to discontinue DUOPA.

    Tell your healthcare provider if you have any side effect that bothers you or does not go away.

    These are not all of the possible side effects of DUOPA. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store DUOPA?

    • Store DUOPA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Do not freeze.
    • Use at room temperature. Take one DUOPA cassette out of the carton and out of the refrigerator 20 minutes prior to use. Use the product at room temperature or you may not get the right amount of medication.
    • Protect the cassette from light and keep it in the carton before using.
    • Use DUOPA before the expiration date printed on the cassette.

    Keep DUOPA and all medicines out of the reach of children.

    General information about the safe and effective use of DUOPA.

    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DUOPA for a condition for which it was not prescribed. Do not give DUOPA to other people, even if they have the same symptoms that you have. It may harm them.

    This Medication Guide summarizes the most important information about DUOPA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about DUOPA that was written for healthcare professionals.

    For more information go to www.DUOPA.com or call 1-844-386-4968.

    What are the ingredients in DUOPA?

    Active ingredients: carbidopa and levodopa

    Inactive ingredients: carmellose sodium and purified water


    This Medication Guide has been approved by the U.S. Food and Drug Administration.

    Manufactured by AbbVie Inc., North Chicago, IL 60064, USA
    or by Fresenius Kabi Norge AS, 1788 Halden, Norway
    For AbbVie Inc.
    North Chicago, IL 60064, USA

    03-B402 Revised: September 2016

    INSTRUCTIONS FOR USE

    DUOPA
    (carbidopa and levodopa) enteral suspension

    These instructions are for use along with any other instructions your healthcare provider gives you.
    Please read the Medication Guide before you start using DUOPA and each time you get a refill.
    For questions or problems, call DUOPA support toll free at 1-844-386-4968.
    pifu fig a
    The CADD-Legacy® 1400 pump is used for delivery of DUOPA through a tube into your stomach attached to the longer colored connector. Enteral nutrition should only be given by the shorter white connector (see Figure A).
    This Instructions for Use provides information for the CADD-Legacy® model 1400 pump only. There are other CADD-Legacy® pump models available. Read the label on the back of the pump to make sure it is a model 1400 pump.
    Your healthcare provider prescribed DUOPA for you. Your healthcare provider programs your prescription into the CADD-Legacy® 1400 pump. The CADD-Legacy® 1400 pump is approved for use with DUOPA. DUOPA is provided as medication inside cassettes that connect to the CADD-Legacy® 1400 pump.
    The pump delivers DUOPA in 3 ways:
    • Continuous Rate: Steady delivery of DUOPA delivered throughout the day while pump is on
    • Morning Dose: A large dose of DUOPA given each morning
    • Extra Dose: A small dose of DUOPA given as needed during the day
    You will need the following items to complete these steps:
    • Pump
    • DUOPA cassette
    • Coin, like a quarter
    • Carrying bag
    • Syringe
    • Syringe connector
    • Room temperature water

    CADD-Legacy®-1400 Pump  
    cadd-legacy-1400-pump
    description of pump keys
    Display

    The display shows programming information and messages. The main screen, which the pump displays most of the time, shows the following:

    display-screen
    DUOPA Cassette
    The single-use DUOPA cassette is for use with the CADD-Legacy® 1400 pump.
    Battery Compartment
    Two AA batteries fit into the battery compartment.
    Cassette Latch
    The cassette latch secures the DUOPA cassette to the pump.

    WARNINGS and CAUTIONS


    Failure to follow the Warnings and Cautions below could cause return of your symptoms, damage to the pump, serious injury, or may lead to death in rare cases.


    WARNINGS

    • Only use the pump in a manner described in this Instructions for Use, after you have received training by your healthcare provider.
    • To avoid explosion hazard, do not use the pump near flammable explosive gases.
    • Only use extension sets that are approved for use with DUOPA (See the Full Prescribing Information for DUOPA), pay attention to all warnings and cautions associated with their use.
    • Always have new batteries available for replacement. If power is lost, DUOPA will not be delivered.
    • If the pump is dropped or hit, the battery door or tabs may break. Do not use the pump if the battery door or tabs are damaged because the batteries will not be correctly secured. This may cause loss of power and DUOPA will not be delivered.
    • If the pump is dropped or hit, look at the pump for damage. Do not use a pump that is damaged or is not functioning correctly.
    • If a gap is present between the battery door and the pump housing, this means the door is not correctly latched. If the battery door becomes detached or loose, the batteries will not be correctly secured. This could cause loss of power and DUOPA will not be delivered.
    • Use only DUOPA cassettes for pump accuracy and to make sure the pump works correctly. Attach the DUOPA cassette correctly. A detached or incorrectly attached DUOPA cassette could cause a problem with getting your DUOPA.

    CAUTIONS

    • Use only Smiths Medical accessories and replacement parts for the pump as using other brands may adversely affect the operation of the pump.
    • Do not operate the pump at temperatures below 36°F (2°C) or above 104°F (40°C).
    • Do not store the pump at temperatures below -4°F (-20°C) or above 140°F (60°C). Do not store the pump with a DUOPA cassette attached. Use the protective cassette provided when storing the pump.
    • Do not keep the pump in humidity levels below 20% or above 90% relative humidity.
    • Do not place the pump in cleaning fluid or water, or allow solution to soak into the pump, keypad, or battery compartment.
    • Do not clean the pump with acetone, other plastic solvents, or abrasive cleaners.
    • Do not use rechargeable NiCd or nickel metal hydride (NiMH) batteries. Do not use carbon zinc (heavy duty) batteries. They do not provide enough power for the pump to operate correctly.
    • Do not store the pump for long periods of time with the batteries installed. Battery leakage could damage the pump.
    Morning Procedure    
    • Take the DUOPA carton containing the DUOPA cassettes out of the refrigerator. Check the expiration date on the carton. Do not use any of the cassettes if the expiration date has passed.
    • Take a DUOPA cassette out of the carton. Return the carton with the remaining cassettes to the refrigerator. Do not use the cassette if the expiration date has passed or the cassette is damaged or empty. Leave the DUOPA cassette at room temperature for 20 minutes before using.
    • Each DUOPA cassette may be used for up to 16 hours after removal from the refrigerator.

    WARNING: Use only DUOPA cassettes to make sure the pump works correctly.

    1) Remove the cassette clip (see Figure B):
    • Remove the cassette tube from its slot in the clip.
    • Pull the clip from cassette to slide it off of the cassette top.
    figure-b
    2) Attach the DUOPA cassette to the pump (see Figure C):
    • Hold the pump so the latch faces up.
    • Hold the DUOPA cassette so the tube points down.
    • Insert the DUOPA cassette hooks into the hinge pins at the base of the pump.
    figure-c
    3) Latch the DUOPA cassette into the pump:
    • Hold the pump and DUOPA cassette upright against a flat surface.
    • Press down on the pump, until the DUOPA cassette fits tightly against the pump (see Figure D).
    • Use a coin to twist the latch counterclockwise until the latch lines up straight with the arrow (see Figure E).
    figure d figure e
    WARNING: Attach the DUOPA cassette correctly. A detached or incorrectly attached cassette could cause a problem with getting your DUOPA.
    4) Remove the red cap on the end of the cassette tube (see Figure F). Save the red cap for use when you throw away the cassette.
    WARNING: Do not connect the red cap to the stomach tube. It will block DUOPA flow.
    figure-f
    5) Connect the stomach tube to the cassette tube:
    • While holding the stomach tube steady, twist off the white cap on the end of the longer colored connector (see Figure G). WARNING: Do not twist the stomach tube.
    • Connect the cassette tube to the end of the longer colored connector (see Figure H). Do not connect to the shorter white connector.
    figure g figure h
    6) Turn the pump on:
    • Press and hold on off buttonuntil the display turns on.
    • Wait approximately 30 seconds for the pump to review settings.
    • Check for stopped screenon the screen.
    PUMP STATUS: The pump is now on but not yet delivering DUOPA.
       
    7) Inspect the tubing for kinks or closed clamps. If needed straighten kinks or open clamps (see Figure I). figure i
    8) Start the pump:
    • Press and holdstop-start-buttonuntil 3 dashes appear and then disappear from the screen.
    • Wait approximately 15 seconds for the pump to start running.
    • Check for run-screenon the display.
       
    PUMP STATUS: The pump is now running. DUOPA delivery will begin as programmed by your healthcare provider. If the pump will not start, a message should appear on the display. Refer to the Alarms and Messages section.
    It will take between 10 minutes and 30 minutes to deliver your morning dose. To start delivery of your Morning Dose you will need to press the Morning Dose key 2 times.
    NOTE: If you are unable to deliver your Morning Dose, it may be too soon since the last Morning Dose to deliver another dose. You may need to wait longer. The time between Morning Doses is decided by your healthcare provider.
    9) The first key press shows the Morning Dose on the display.
    • Press morning dose button
    • Check for morning dose screenon the display. The number on your display is the Morning Dose of DUOPA your healthcare provider prescribed for you.
       
    10) The second key press starts Morning Dose delivery.
    • Press morning dose buttona second time to deliver the Morning Dose.
    • The display morning dose screenshows a countdown of your Morning Dose.
       
    PUMP STATUS: After the Morning Dose finishes, the pump will automatically begin delivering the Continuous Rate. RUN will appear on the display. This completes DUOPA delivery for your Morning Procedure.
    11) Insert pump into the carrying bag (see Figure J).
    • Other carrying cases are also available. Refer to the specific Instructions for Use, which accompanies your carrying case.
    figure j
    12) Wear the bag over your shoulder or neck:
    • Place the bag strap over your shoulder or neck (see Figure K).
    • Make sure the pump is in correct position (see Figure L).
    figure k
    figure l
    Extra Dose
    1) Give an Extra Dose of DUOPA:
    NOTE: If you are unable to deliver the Extra Dose, it may be too soon since the last Extra Dose to deliver another and you may need to wait longer. The time between Extra Doses and the amount of DUOPA in the Extra Dose is decided by your healthcare provider.
    • Check for pifu run screenon the display.
    • Press extra dose button
    • Listen for 2 beeps.
    • The display will show dose screen
    PUMP STATUS: The pump is now delivering the Extra Dose. When it finishes, RUN will appear on the display and the Continuous Rate will continue to run.

    For instructions on changing a DUOPA cassette, see Changing the Cassette.


    Evening Procedure    
    You will need:
    • 1 Syringe
    • 1 Syringe connector
    • Room temperature water
    • 1 Coin, like a quarter
       
    1) Remove the pump from the carrying bag (see Figure M).   figure m
    2) Stop the Continuous Rate:
    • Press and holdstop start buttonuntil 3 dashes appear and then disappear from the display.
    • Check for stopped screenon the display.
       
    3) Turn the pump off:
    • Press and holdon off buttonuntil 3 sets of dots appear and then disappear from the display and the display turns off.
    • Check that the display is off.
       
    4) Clamp the cassette tube (see Figure N). figure n
    5) Disconnect the tubing:
    • Twist the cassette tube to disconnect it from the longer colored connector (see Figure O). WARNING: Do not twist the stomach tube.
    • Replace the red cap on the cassette tube.
    figure o
    6) Flush the longer colored connector:
    • Connect the syringe connector to the longer colored connector.
    • Fill a syringe with room temperature tap or drinking water. Do not use hot water as it could burn the wall of your stomach or intestine.
    • Connect the syringe to the syringe connector (see Figure P). Do not over-tighten the syringe connector or it could break. Do not use the syringe connector if it is cracked or broken.
    • Push the syringe plunger to flush the tube. Do not force the syringe if flushing the tube is difficult. Call your healthcare provider if you are unable or have difficulty flushing your tube.
    • Remove the syringe and the syringe connector.
    • Replace the white cap on the longer colored connector (see Figure Q).
    figure p figure q
    7) Flush the shorter white connector:
    • Twist the white cap off the shorter white connector.
    • Connect the syringe connector to the shorter white connector.
    • Fill a syringe with room temperature tap or drinking water. Do not use hot water as it could burn the wall of your stomach or intestine.
    • Connect the syringe to the syringe connector (see Figure R). Do not over-tighten the syringe connector or it could break. Do not use the syringe connector if cracked or broken.
    • Push the syringe plunger to flush the tube.
    • Remove the syringe and the syringe connector.
      Replace the white cap on the shorter white connector (see Figure S).
    figure r figure s
    8) Remove the DUOPA cassette from the pump:
    • Hold the pump and DUOPA cassette upright against a flat surface (see Figure T).
    • Use a coin to twist the latch clockwise until the latch pops out (see Figure U).
    • Remove the DUOPA cassette from the pump.
    figure-t
    figure u
    Changing the DUOPA Cassette
    • Take the DUOPA carton containing the DUOPA cassette out of the refrigerator. Check the expiration date on the carton. Do not use any of the cassettes if the expiration date has passed.
    • Take a DUOPA cassette out of the carton. Return the carton with the remaining cassettes to the refrigerator. Do not use the cassette if the expiration date has passed or the cassette is damaged or empty. Leave the DUOPA cassette at room temperature for 20 minutes before using.
    • Each DUOPA cassette may be used for up to 16 hours after removal from the refrigerator.

    WARNING: Use only DUOPA cassettes to make sure the pump works correctly.

    1) Remove the pump from the carrying bag (see Figure V). figure v
    2) Stop the Continuous Rate:
    • Press and holdstop start buttonuntil 3 dashes appear and then disappear from the display.
    • Check for stopped screenon the display.
       
    3) Turn the pump off:
    • Press and holdon off buttonuntil 3 sets of dots appear and then disappear from the display and the display turns off.
    • Check that the display is off.
       
    4) Clamp the cassette tube (see Figure W). figure w
    5) Disconnect the tubing:
    • Twist the cassette tube to disconnect it from the longer colored connector (see Figure X). WARNING: Do not twist the stomach tube.
    • Replace the red cap on the cassette tube.
    figure x
    6) Remove the DUOPA cassette from the pump:
    • Hold the pump and DUOPA cassette upright against a flat surface (see Figure Y).
    • Use a coin to twist the latch clockwise until the latch pops out (see Figure Z).
    • Remove the DUOPA cassette from the pump.
    figure y figure z
    7) Remove the cassette clip on the new DUOPA cassette (see Figure AA):
    • Remove the cassette tube from its secured slot in the clip.
    • Pull the clip from the cassette to slide it off of the cassette top.
    figure-aa
    8) Attach the new DUOPA cassette to the pump (see Figure BB):
    • Hold the pump so that the latch faces up.
    • Hold the DUOPA cassette so that the tube points down.
    • Insert the DUOPA cassette hooks into the hinge pins at the base of the pump.
    figure bb
    9) Latch the new DUOPA cassette into the pump:
    • Hold the pump and DUOPA cassette upright against a flat surface.
    • Press down on the pump until the DUOPA cassette fits tightly against the pump (see Figure CC).
    • Use a coin to twist the latch counterclockwise until the latch lines up straight with the arrow (see Figure DD).

    WARNING: Attach the DUOPA cassette correctly. A detached or incorrectly attached cassette could cause a problem with getting your DUOPA.
    figure cc figure dd
    10) Remove the red cap on the end of the cassette tube (see Figure EE).
    Save the red cap to use when discarding the cassette.
    WARNING: Do not connect the red cap to the stomach tube as it will block DUOPA flow.
    figure ee
    11) Connect the stomach tube to the cassette tube:
    • While holding the stomach tube steady, twist off the white cap on the end of the longer colored connector (see Figure FF). WARNING: Do not twist the stomach tube.
    • Connect the cassette tube to the end of the longer colored connector (see Figure GG). Do not connect to the shorter white connector.
    figure ff figure gg
    12) Turn the pump on:
    • Press and holdon off buttonuntil the display turns on.
    • Wait approximately 30 seconds for the pump to review settings.
    • Check for stopped screenon the display.
    PUMP STATUS: The pump is now on but not delivering DUOPA.
       
    13) Inspect the tubing for kinks or closed clamps. If needed straighten kinks or open clamps (see Figure HH). figure hh
    14) Start the pump:
    • Press and holdstop start buttonuntil 3 dashes appear and then disappear from the display.
    • Wait approximately 15 seconds for pump to start running.
    • Check for run screenon the display.
    PUMP STATUS: The pump is now running.
       
    15) Insert the pump into the carrying bag (See Figure II). figure ii
    16) Wear the bag on your shoulder or neck:
    • Place the bag strap over your shoulder or neck (see Figure JJ).
    • Make sure the pump is in correct position (see Figure KK).
    figure jj figure kk
    Changing the Batteries:
    If you see LowBat or Battery Depleted on the display, change the batteries. Use 2 new AA alkaline batteries such as DURACELL® or EVEREADY® ENERGIZER®. The pump keeps all the important information when the batteries are removed.

    WARNING:
    • Always have new batteries available for replacement. If power is lost, DUOPA will not be delivered.
    • If the pump is dropped or hit, the battery door or tabs may break. Do not use the pump if the battery door or tabs are damaged because the batteries will not be correctly secured. This may lead to loss of power and DUOPA will not be delivered.
    • If a gap is present anywhere between the battery door and the pump housing, the door is not correctly latched. If the battery door becomes detached or loose, the batteries will not be correctly secured. This could cause loss of power and DUOPA will not be delivered.

    CAUTION:
    • Do not use rechargeable NiCd or nickel metal hydride (NiMH) batteries. Do not use carbon zinc (“heavy duty”) batteries. They do not provide enough power for the pump to operate correctly.
    • Do not store the pump for prolonged periods of time with the batteries installed. Battery leakage could damage the pump.
    1) Ensure the pump is stopped.  
    2) Push and hold the arrow button while sliding the battery door until it comes completely off the pump (see Figure LL). figure ll
    3) Remove the used batteries (see Figure MM). figure mm
    4) Install new batteries into the battery compartment.
    NOTE: Insert the batteries correctly based on the picture in the battery compartment. If you insert the batteries backwards, the display will remain blank. Reinsert the batteries, making sure to match the + and markings with the battery compartment picture.
    5) Listen for a beep.
    PUMP STATUS: The pump is now powered. The power-up sequence will start, the pump will go through an electronic self-test, and then the pump will beep 6 times at the end of the power-up sequence. All of the display indicators, the software revision, and each setting will appear briefly.
    If you do not hear a beep, and the display is off, the pump is not powered. Check that the batteries are correctly inserted.
    6) Slide the battery door back onto the pump into its original closed position (see Figure NN). figure nn
    Change the Morning Dose    
    Your healthcare provider may have set your pump to allow for dose changes to your Morning Dose and Continuous Rate (Lock Level 1). Do not change your medicine dose without approval and training from your healthcare provider.
    Talk with your healthcare provider to decide when to change your Morning Dose and Continuous Rate. Do not change your Extra Dose unless your healthcare provider tells you to. If your Extra Dose requires changes, your healthcare provider will provide instructions.
    Change the Morning Dose
    WARNING: Do not use the Prime button. Priming is for use by your healthcare provider only.
    1) Turn the pump on:
    • Press and holdon off button until the display turns on.
    • Wait approximately 30 seconds for pump to review settings.
    • Check for stopped screenon the display.

    PUMP STATUS: The pump is now on but not yet delivering DUOPA.
       
    2) Inspect the tubing for kinks or closed clamps. If needed, straighten kinks or open clamps (see Figure OO). figure oo
    3) Start the pump:
    • Press and holdstop start buttonuntil 3 dashes appear and then disappear from the display.
    • Wait approximately 15 seconds for pump to start running.
    • Check for run screenon the display.
    PUMP STATUS: The pump is now running.
       
    4) Change the Morning Dose:
    1. Press morning dose button1 time.
    2. Check for morning dose screenon the display.
    3. Press up button or down buttonto select the desired Morning Dose.
    4. Press enter clear buttonto store the Morning Dose.
    5. Make sure you see the correct Morning Dose on the display. If not, repeat Steps 4c to 4e.
       
    5) Deliver the Morning Dose:
    • Press morning dose button1 time.
      NOTE: If you see “Value not saved” on the display, press NEXT and then repeat Steps 4c to 4e.
    • The display morning dose screenshows a countdown of your Morning Dose.
    PUMP STATUS: After the Morning Dose finishes, the pump will begin delivering the Continuous Rate. RUN will appear on the display.
    NOTE: If you are unable to deliver a Morning Dose, it may be too soon since the last Morning Dose to deliver another and you may need to wait longer. The time between Morning Doses is decided by your healthcare provider.
       
    Change the Continuous Rate    
    1) Stop the Continuous Rate:
    • Press and hold stop start buttonuntil 3 dashes appear and then disappear from the display.
    • Check for stopped screen on the display.
       
    2) Change the Continuous Rate:
    1. Press next button2 times.
    2. Check for continuous rate screenon the display.
    3. Press up button or down buttonto select the desired Continuous Rate.
    4. Press enter clear buttonto store the Continuous Rate.
    5. Make sure you see the desired Continuous Rate on the display. If not, repeat Steps 2c to 2e.
       
    3) Start the pump:
    • Press and holdstop start button until 3 dashes appear and then disappear from the display.
      NOTE: If you see “Value not saved” on the display, press NEXT and then repeat Steps 2c to 2e.
    • Wait approximately 15 seconds for the pump to start running.
    • The display will show run screen
    PUMP STATUS: The pump is now running.
       
    Alarms and Messages
    The table below shows some of the common alarms that you may hear from the pump. With all alarms, read the display before pressing next button to silence the alarm.
    What you see: What you hear: Meaning Response
    Error Two-Tone Alarm An error with the pump has occurred. Contact your healthcare provider.
    High Pressure Two-Tone Alarm There is pressure backed up in the tubing. Check tubing for clamps, kinks, or blockages. Make sure the red cap has been removed from the DUOPA cassette tube. Flush connectors if necessary. If it is not possible to flush the tubes, contact your healthcare provider as your tube may be blocked.
    LowBat 3 Two-Tone Beeps Every 5 minutes The pump batteries are low. Change the batteries right away.
    Upstream Occlusion Two-Tone Alarm If your healthcare provider has the Upstream Occlusion Sensor set to ON and a blockage in the DUOPA cassette is detected, this alarm will sound. Detach the DUOPA cassette. Check if the DUOPA cassette is empty. If not empty, reattach the DUOPA cassette. Restart the pump to continue delivery. Contact your healthcare provider if the alarm continues.
    No message on display Two-Tone Alarm Batteries were removed within approximately 15 seconds after stopping the pump. Install new batteries to silence the alarm. Otherwise, the alarm will stop within a short period of time.
    Display shows current pump status 2 Beeps (Long-Short) The DUOPA cassette is not lined up with the pump or DUOPA is not flowing from the DUOPA cassette to the pumping mechanism.
    Very cold or extremely thick DUOPA may cause this alarm as well.
    Press NEXT to silence the alarm. The pump continues to run. Make sure the DUOPA cassette is correctly lined up with the pump and DUOPA is flowing.
    Take the DUOPA cassette out of the refrigerator for 20 minutes before attaching to the pump.
    Battery Depleted Two-Tone Alarm Batteries are dead. Install new batteries. To continue delivery, restart the pump when completed.
    Key pressed, Please release Two-Tone Alarm Key is being held down. Stop pressing key. If the alarm persists, close the cassette tube clamp and remove the pump from use. Contact your healthcare provider.
    No Disposable, Clamp Tubing Two-Tone Alarm Disposable refers to the DUOPA Cassette. No Disposable means the DUOPA cassette was removed. The pump is not sensing proper cassette attachment. Clamp the cassette tube and disconnect it from your stomach tube. A DUOPA cassette must be correctly attached in order for the pump to run. Press NEXT to silence the alarm.
    No Disposable, Pump won't run Two-Tone Alarm Disposable refers to the DUOPA Cassette. You have tried to start the pump without a disposable DUOPA cassette attached. Press NEXT to silence the alarm. A DUOPA cassette must be correctly attached for the pump to run.
    Service Due See manual Two-Tone Alarm The pump is scheduled for service. Press NEXT to silence the alarm. The pump is still working, but contact your healthcare provider for further instructions.
    Frequently Asked Questions
    What if I drop the pump or hit it against a hard surface?
    Do the following right away:
    • Check the DUOPA cassette latch on the side of the pump and make sure the line on the latch lines up with the arrow on the side of the pump.
    • Gently twist, push, and pull on the DUOPA cassette to make sure it is still firmly attached.
    • Check the battery door to make sure it is still firmly attached.
    If the DUOPA cassette or the battery door is loose or damaged, do not use the pump.
    Stop the pump right away, close the tubing clamp, and contact your healthcare provider.
    What should I do if I drop the pump in water?
    • If you accidentally drop the pump in water, pick it up quickly, dry it off with a towel, and call your healthcare provider.
    WARNING: If the pump is dropped or hit, look at the pump for damage. Do not use a pump that is damaged or is not working correctly.
    What should I do if I need to bathe while wearing the pump?
    You’ll need to detach the pump before you shower, bathe, or swim. Reattach the pump to the stomach tubing afterwards and restart it.
    What should I do if I need to have a medical test while wearing the pump?
    The pump may need to be removed prior to certain medical tests. Be sure to talk to your doctor about your DUOPA pump before you take these tests.
    STORAGE and DISPOSAL
    Storage
    • Store DUOPA in the refrigerator with the temperature between 36°F to 46°F (2°C to 8°C).
    • When the DUOPA cassette has been removed from the refrigerator, DUOPA should be used within 16 hours.
    • The DUOPA cassettes are for single use only and should not be used for longer than 16 hours, even if some of the medicine remains. An opened cassette should not be re-used.
    • Protect the cassette from light and keep it in the carton before using.
    Throwing away your DUOPA cassette or batteries
    • Throw away the DUOPA cassette as your healthcare provider tells you to.
    • Throw away used batteries in a manner safe for the environment, and according to any regulations that apply.

    This Instructions for Use has been approved by the U.S. Food and Drug Administration.


    abbvie AbbVie Inc.
    North Chicago, IL 60064, U.S.A.
    For DUOPA Support: 1-844-386-4968





     
    Pump manufactured by:
    Smiths Medical ASD, Inc.
    1265 Grey Fox Road
    St. Paul, MN 55112 USA
    Tel: 1-800-258-5361
    www.smiths-medical.com
       

    03-B169 Revised: May 2015

    Legacy 1400 Operator's Manual

    CADD-Legacy® 1400 Pump
    Model 1400

    This online version differs from the printed version. Certain information that is not intended for patients has been removed.

    This operator’s manual is for clinician use only. Read the entire operator’s manual before operating the pump.

    This manual pertains only to the CADD-Legacy® 1400 pump. There are other CADD-Legacy® pump models available; review the rear label of the pump to ensure it is a CADD-Legacy® 1400 pump before programming. This pump is designed for enteral delivery of medication and can be programmed to deliver a continuous rate, a morning dose, and extra doses.

    This manual is intended for clinician use only. Do not permit patients to have access to this manual. The pump has 3 security levels designed to limit patient access. Do not disclose the pump’s security codes or any other information that would allow inappropriate access to programming and operating functions.

    The issue date of this operator’s manual is included on the back cover for the clinician’s information. In the event one year has elapsed between the issue date and product use, the clinician should contact Smiths Medical to see if a later revision of this manual is available.

    Technical Assistance

    If you have comments or questions concerning the operation of the CADD-Legacy® 1400 pump, please call the number given below. When calling, please specify the pump’s software revision. This information is located on the pump’s display during power up.

    Our staff at Smiths Medical is available to help clinicians 24 hours a day with the programming and operation of the CADD-Legacy® 1400 pump.

    Smiths Medical ASD, Inc.
    1265 Grey Fox Road
    St. Paul, MN 55112 USA
    Tel: 1 800 258 5361 (USA)
    Tel: +1 614 210 7300
    www.smiths-medical.com

    Read this entire operator’s manual before operating the CADD-Legacy® 1400 pump.

    Failure to follow the warnings and cautions below could result in return of symptoms, damage to the pump, serious injury, or death in extreme cases.

    Please refer to the full prescribing information for DUOPA (carbidopa and levodopa) enteral suspension for indications and usage, contraindications, warnings, precautions, and adverse reactions.

    Warnings

    • This operator’s manual should be used by clinicians only. Do not permit patients to have access to this manual, as the information contained would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.
    • To avoid explosion hazard, do not use the pump in the presence of flammable anesthetics or explosive gases.
    • The CADD-Legacy® 1400 pump and medication cassette reservoir are designed for enteral delivery of medication only. They are NOT intended for IV or other parenteral routes of infusion.
    • Do not disclose to the patient the pump’s security codes or any other information that would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.
    • Always have new batteries available for replacement. If power is lost, non-delivery of medication will occur.
    • If the pump is dropped or hit, the battery door or tabs may break. Do not use the pump if the battery door or tabs are damaged because the batteries will not be properly secured; this may result in loss of power and non-delivery of medication.
    • If a gap is present anywhere between the battery door and the pump housing, the door is not properly latched. If the battery door becomes detached or loose, the batteries will not be properly secured; this could result in loss of power and non-delivery of medication.
    • System delivery inaccuracies beyond the stated accuracy may occur as a result of back pressure or fluid resistance, which depends upon temperature, medication viscosity, catheter size, extension set tubing, flow rate, and orientation of the pump system.
    • Programming the pump at a delivery rate other than what is prescribed will cause over- or under-delivery of medication.
    • Clamp the fluid path tubing and/or disconnect the tubing from the enteral access device before removing the medication cassette reservoir from the pump to prevent unintended delivery of medication.
    • Use only approved DUOPA medication cassette reservoirs to maintain pump accuracy and assure proper pump operations.
    • Use only extension sets approved for use with DUOPA, paying particular attention to all warnings and cautions associated with their use.
    • Attach the cassette properly. The cassette is the part of the medication cassette reservoir that attaches to the pump. A detached or improperly attached cassette could result in unintended delivery of medication.
    • Do not prime the fluid path with the tubing connected to a patient as this could result in over-delivery of medication.
    • If the pump is dropped or hit, inspect the pump for damage. Do not use a pump that is damaged or is not functioning properly, as this could compromise patient treatment.
    • The use of power supplies and a remote dose cord other than those listed in the electromagnetic emissions declaration may result in increased emissions or decreased immunity of the pump.
    • The pump should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the user should verify normal operation of the pump in the configuration in which it is to be used.
    • There are potential health hazards associated with improper disposal of batteries, electronics, and contaminated (used) reservoirs and extension sets. Dispose of used batteries, reservoirs, extension sets and other used accessories, or a pump that has reached the end of its useful life, in an environmentally safe manner, and according to any regulations that may apply.

    Cautions

    • Use only Smiths Medical accessories and replacement parts, as using other brands may adversely affect the operation of the pump.
    • Do not operate the pump at temperatures below 2°C (36°F) or above 40°C (104°F).
    • Do not store the pump at temperatures below -20°C (-4°F) or above 60°C (140°F). Do not store the pump with the medication cassette reservoir attached. Use the protective cassette provided.
    • Do not expose the pump to humidity levels below 20% or above 90% relative humidity.
    • Do not sterilize the pump or medication cassette reservoir as this could cause damage.
    • When the upstream occlusion sensor is turned off, the pump will not detect occlusions in the medication cassette reservoir. Periodically inspect the medication cassette reservoir for decreasing volume. Undetected occlusions could result in under- or non-delivery of medication.
    • Do not use rechargeable NiCd or nickel metal hydride (NiMH) batteries. Do not use carbon zinc (“heavy duty”) batteries. They do not provide sufficient power for the pump to operate properly.
    • Do not store the pump for prolonged periods of time with the batteries installed. Battery leakage could damage the pump.
    • Prior to starting medication delivery, inspect the fluid path for kinks, a closed clamp, or other obstruction. An undetected occlusion may result in under- or non-delivery of medication and/or nuisance alarms.
    • When you enter a new value, any lockout time already in effect will be cleared. An extra dose or morning dose could be requested and delivered immediately upon starting the pump, which may result in over-delivery of medication.
    • Do not immerse the pump in cleaning fluid or water. Do not allow solution to soak into the pump, accumulate on the keypad, or enter the battery compartment. Moisture buildup inside the pump may damage the pump.
    • Do not clean the pump with acetone, other plastic solvents, or abrasive cleaners, as damage to the pump may occur.
    • Do not expose the pump to ther­apeutic levels of ionizing radiation as permanent damage to the pump’s electronic circuitry may occur. The best procedure to fol­low is to remove the pump from the patient during therapeutic radia­tion sessions. If the pump must remain in the vicinity during a ther­apy session, it should be shielded, and its ability to function properly should be confirmed following treatment.
    • Do not expose the pump directly to ultrasound, as permanent damage to the electronic circuitry may occur.
    • Do not use the pump in the vicinity of magnetic resonance imaging (MRI) equipment as magnetic fields may adversely affect the operation of the pump. Remove the pump from the patient during MRI procedures and keep it at a safe distance from magnetic energy.
    • This pump may interfere with ECG equipment. Monitor ECG equipment carefully when using this pump.
    • CADD-Legacy® 1400 pumps are sealed units. A broken or damaged seal will, therefore, be considered conclusive evidence that the pump has been misused and/or altered, which voids any and all warranties. All service and repair of CADD-Legacy® 1400 pumps must be performed by Smiths Medical or its authorized agents.
    • Review programming screens when complete to make sure desired programming has been entered. Check to make sure unintended changes were not made to the morning dose, continuous rate, or extra dose volume. If unintended changes were made, go to the appropriate screen and program the desired value.

    Table of Contents
    Warnings
     
    Cautions
     
    1.0 General Description
    Introduction
    Indications
    Symbols
    Pump Diagram
    Description of the Keys, Display, and Features
    The Main Screen
    Lock Levels
    Security Codes
    Lock Level 0 (LL0) Table
    Lock Levels 1 and 2 (LL1, LL2) Table
     
    2.0 Pump Setup and Programming
    Installing or Replacing the Batteries
    Watching Power Up
    Changing to Lock Level 0 (LL0)
    Programming the Pump: General Instructions
    Delivery Methods
    Programming Screens
    Programming Delivery
    Programming a Morning Dose
    Removing a Medication Cassette Reservoir
    Attaching a Medication Cassette Reservoir
    Priming the Tubing and Connecting to the Patient
    Setting the Lock Level for the Patient
    Programming with Upper Limits, Adjusting Doses in Lock Level 1
     
    3.0 Operating the Pump
    Starting the Pump
    Stopping the Pump
    Turning the Pump On/Off
    Starting a Morning Dose
    Starting an Extra Dose
    Stopping an Extra Dose or Morning Dose
    Resetting the Reservoir Volume
     
    4.0 Biomed Functions
    Overview: Accessing the Biomed Functions and Programming the Lockouts
    Extra Dose Lockout
    Morning Dose Lockout
    Upstream Occlusion Sensor On/Off
     
    5.0 Reference
    Messages and Alarms, Alphabetical List
    What if the pump is dropped or hit?
    Cleaning the Pump and Accessories
    Exposure to Radiation, Ultrasound, Magnetic Resonance Imaging (MRI), or Use near ECG Equipment
    Continuous Rate Scroll Ranges
    Extra Dose, Morning Dose Scroll Ranges
    Technical Description
    Specifications (Nominal)
    Accuracy Test Results
    Electromagnetic Emissions and Immunity Declarations
    Safety Features and Fault Detection
    Software Safety Features
    Data Handling Software Safety Features
     Annual Functional Inspection
    Collect Separately
    Limited Warranty
    Index
     
    Appendix A – Pump Programming Quick Reference for Healthcare Providers

    1.0 General Description

    Introduction

    The CADD-Legacy® 1400 pump provides enteral delivery of medication to patients in hospital or outpatient settings. Therapy should always be overseen by a physician or a certified, licensed healthcare professional. As appropriate to the situation, the patient should be instructed in using and troubleshooting the pump.


    Indications

    The CADD-Legacy® 1400 pump is indicated solely for the enteral delivery of medication contained in a medication cassette reservoir supplied by AbbVie. The medication cassette reservoir attaches to the bottom of the pump.

    WARNING: The CADD-Legacy® 1400 pump and medication cassette reservoir are designed for enteral delivery of medication only. They are NOT intended for IV or other parenteral routes of infusion. Use of this product for medications or therapies outside the intended use can result in death or serious patient injury.

    Refer to AbbVie’s full prescribing information for DUOPA (carbidopa and levodopa) enteral suspension for indications and usage, contraindications, warnings, precautions, and adverse reactions.


    Symbols

    power jack Direct current (power jack)
    accessory jack Accessory jack
    caution Caution
    class II equipment Class II equipment
    type CF equipment Type CF equipment
    splashproof Splashproof – water splashed against the pump housing will have no harmful effects (see Cleaning the Pump and Accessories, Section 5, for additional important information).
    catalog number Catalog number
    serial number Serial number
    manufacture date Date of manufacture
    manufacturer Manufacturer
    RX only CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
    collect separately Collect separately
    temperature limitation Temperature limitation
    humidity limitation Humidity limitation
    pressure limitation Atmospheric pressure limitation
    mr unsafe MR Unsafe

    Pump Diagram

    pump diagram

    Description of the Keys, Display, and Features

    AC Indicator Light

    The green indicator light is on when you are using the AC adapter to power the pump.

    Display

    The liquid crystal display (LCD) shows programming information and messages. In this manual, the term “display” is synonymous with display panel or LCD.

    Keypad

    The keys on the keypad are described below. A key beeps when pressed if it is operable in the current lock level.

    stop start-2 used to start and stop pump delivery; silences alarms.
    enter clear-2 used to enter (save) a new value in the pump’s memory when programming doses or pump settings or to clear values from record-keeping screens. It is also used to return from the biomed functions to the main screen (see Section 4).
    prime used to fill the tubing with medication.
    morning dose-2 used to confirm and deliver the morning dose (typically used as a daily loading dose) when the pump is running. When the pump is stopped, it is used to view or change the pump’s current lock level. Lock levels are used to limit patient access to certain programming and operating functions. (See Lock Levels, this section.)
    next-2 used to move from one programming screen to the next without changing the setting or value displayed; silences alarms.
    up button-2 used to “scroll up” or increase a value, or scroll through biomed function settings.
    down button-2a used to “scroll down” or decrease a value, or scroll through biomed function settings.
    on off-2 used to put the pump into a low power state when not in use or back into full power.
    extra dose-2 used by the patient to deliver a programmed amount of medication upon request (extra dose).

    Power Jack

    You may plug an AC adapter into the power jack as an alternate source of power. The indicator light on the front of the pump will illuminate when the AC adapter is in use.

    Accessory Jack

    The accessory jack is used for attaching accessory cables. See the instructions for use supplied with those accessories.

    Medication Cassette Reservoir

    The medication cassette reservoir is the single-use reservoir designed for use with the CADD-Legacy® 1400 pump. In this manual and on the pump’s display, the word “disposable” refers to the medication cassette reservoir. In AbbVie’s patient instructions for use, medication cassette reservoir is referred to as DUOPA cassette.

    Battery Compartment

    Two AA batteries fit into the battery compartment. The AA batteries serve as the primary source of power, or as backup power when an AC adapter is in use.

    Cassette Latch

    The cassette latch attaches the cassette to the pump. The term “cassette” refers to the part of the medication cassette reservoir that attaches to the bottom of the pump. If the cassette becomes unlatched while the pump is running, delivery will stop and an alarm will occur. If the cassette becomes unlatched while the pump is stopped, an alarm will occur.

    Other Features Not Shown

    Upstream Occlusion Sensor: The pump contains an upstream occlusion sensor. This feature may be turned on or off (see Section 4, Biomed Functions). When the sensor is turned on, and an occlusion in the reservoir is detected, an alarm will sound, delivery will stop, and the display will show Upstream Occlusion.

    CAUTION: When the upstream occlusion sensor is turned off, the pump will not detect occlusions in the medication cassette reservoir. Periodically inspect the medication cassette reservoir for decreasing volume. Undetected occlusions could result in under- or non-delivery of medication.

    Downstream Occlusion Sensor: The pump contains a downstream occlusion sensor. When a downstream occlusion (between the pump and the patient) is detected, an alarm will sound, delivery will stop, and the display will show High Pressure.

    Reservoir Volume Alarm: The reservoir volume alarm indicates when the volume of medication in the medication cassette reservoir is low or depleted. Each time you change the medication cassette reservoir, you may reset the reservoir volume to the originally programmed value. Then, as medication is delivered, the reservoir volume automatically decreases. When the pump calculates that 5 ml remain in the medication cassette reservoir, beeps sound and ResVol Low appears on the main screen. This alarm recurs at every subsequent decrease of 1 ml until the reservoir volume reaches 0 ml, at which point the pump stops and the reservoir volume empty alarm sounds.

    NOTE: The default setting for Reservoir Volume is Not in Use. The reservoir volume alarm is activated only when a value is programmed into the Reservoir Volume screen. Programming a reservoir volume value is not required for general use, but is available at provider discretion.

    The Main Screen

    The main screen is the starting point for programming or viewing the pump’s settings.

    If no keys are pressed for 2 minutes, the display reverts to the main screen. When the two AA batteries are low, LowBat appears on the main screen.

    main screen running

    *Does not appear on the main screen if reservoir volume is programmed to Not In Use.

    main screen stopped

    Lock Levels

    Lock levels are used to limit patient access to certain programming and operating functions. The table on the next page lists the functions that are accessible in lock level 0 (LL0), lock level 1 (LL1), and lock level 2 (LL2). When a function is accessible, the key associated with the function beeps when pressed. If a function is not accessible, the pump ignores the key press and a beep does not sound. Section 2, Pump Setup and Programming, describes how to change the lock level.

    Security Codes

    The following security codes are preset by the manufacturer for the clinician’s use:

    **Text Omitted**

    WARNING: Do not disclose to the patient the pump’s security codes or any other information that would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.

    Lock Level 0 (LL0) Table

    This table lists the operations that are accessible in lock level 0 (LL0) while the pump is stopped and running. LL0 permits complete access to all programming and operating functions.

    Pump Operations and Programming Stopped Running
    LL0 Any Lock Level
    Stop/Start the pump Yes Yes
    Reset reservoir volume Yes No
    Prime Yes No
    Change the lock level Yes, w/code No
    Change morning dose No Yes
    Start an extra dose No Yes
    Start a morning dose No Yes
    Change continuous rate Yes No
    Change extra dose Yes No
    Clear given amount Yes No
    Biomed Functions
    Access to functions Yes, w/code No
    Extra dose lockout Yes, w/code No
    Morning dose lockout Yes, w/code No
    Upstream occlusion Sensor On/Off Yes, w/code No

    Lock Levels 1 and 2 (LL1, LL2) Table

    This table lists the operations that are accessible in lock level 1 (LL1) and lock level 2 (LL2) while the pump is stopped and running. LL1 permits limited control of pump programming and operations. LL2 permits only minimal control of pump operations.

    Pump Operations and Programming Stopped Running
    LL1 LL2 Any Lock Level
    Stop/Start the pump Yes Yes Yes
    Reset reservoir volume Yes Yes No
    Prime Yes No No
    Change the lock level Yes, w/code Yes, w/code No
    Change morning dose No No Yes*
    Start an extra dose No No Yes
    Start a morning dose No No Yes
    Change continuous rate Yes* No No
    Change extra dose Yes* No No
    Clear given amount Yes No No

    *When in LL1, you can program up to the LL0 value. No programming is allowed in LL2.

    2.0 Pump Setup and Programming

    Installing or Replacing the Batteries

    Use new, AA alkaline batteries such as DURACELL® or EVEREADY® ENERGIZER® batteries to power the pump. The pump retains all programmed values while the batteries are removed.

    Dispose of used batteries in an environmentally safe manner, and according to any regulations which may apply.

    WARNING:
    • Always have new batteries available for replacement. If power is lost, non-delivery of medication will occur, which could compromise patient treatment.
    • If the pump is dropped or hit, the battery door or tabs may break. Do not use the pump if the battery door or tabs are damaged because the batteries will not be properly secured; this may result in loss of power and non-delivery of medication, which could compromise patient treatment.
    install batteries
    CAUTION: Do not use rechargeable NiCd or nickel metal hydride (NiMH) batteries. Do not use carbon zinc (“heavy duty”) batteries. They do not provide sufficient power for the pump to operate properly.

    In order to install or replace the batteries, be sure the pump is Stopped. Then, follow these steps:

    1. Push down and hold the arrow button while sliding the door off.

    open battery door

    2. Remove the used batteries. Pulling on the end of the battery strap will make battery removal easier.

    3. Install the new batteries in the compartment, making sure the battery strap is positioned correctly under the batteries.

    install battery with strap

    NOTE:

    • Be sure to match the polarity markings of the new batteries (+ and –) with those labeled in the battery compartment. If you put the batteries in backwards, the display will remain blank, and you will not hear a beep.
    • Use two new, AA alkaline batteries to power the pump. You may use any alkaline batteries, including DURACELL® Alkaline and EVEREADY® ENERGIZER® Alkaline, for example.

    4. Place the battery door over the battery compartment and slide the door closed.
    close battery door

    5. Ensure that the door is latched by trying to remove the door without pressing the arrow button.

    NOTE: The power-up sequence will start, the pump will go through an electronic self-test, and the pump will beep 6 times at the end of the power-up sequence. All of the display indicators, the software revision, and each parameter will appear briefly.

    WARNING: If a gap is present anywhere between the battery door and the pump housing, the door is not properly latched. If the battery door becomes detached or loose, the batteries will not be properly secured; this could result in loss of power and non-delivery of medication, which could compromise patient treatment.
    improper closed battery door

    6. Resume operation of the current program by pressing and holding stop start-3 to start the pump or proceed to program the pump.

    NOTE:

    • The life of the batteries is dependent on the amount of medication delivered, delivery rate, battery age, and the temperature.
    • At the rate of 100 ml per day, alkaline batteries will usually last about 7 days.
    • The power of the batteries will be quickly depleted at temperatures below 10°C (50°F).
    CAUTION: Do not store the pump for prolonged periods of time with the batteries installed. Battery leakage could damage the pump.

    Watching Power Up

    When you install the batteries, the pump will start its power up sequence during which it performs self-tests and displays programmed values. Watch for the following:

    • Pump model number and last error code (“LEC”) if any, will appear. (If an error code appears, the pump should be removed from use and returned for service.)
    • The software revision will appear.
    • The display will turn on, showing a series of blocks. Look for any blank areas, which would indicate a faulty display.
    • The display will turn off briefly.
    • The pump’s program screens will appear, followed by the current lock level setting. The pump will beep after each screen. If messages appear, see Messages and Alarms Table, Section 5 for further explanation and instruction.
    • When power up is complete, 6 beeps will sound, and the pump will be stopped on the main screen.

    NOTE: To move quickly through the power-up screens, press next-3 repeatedly. To skip the automatic review entirely, pressdown button-3aIf you attempt to skip screens before the pump is powered up, it will not respond.

    Changing to Lock Level 0 (LL0)

    Before programming the pump, make sure the pump is set to LL0. LL0 allows the clinician to access all programming and operating functions.

    1. Make sure the pump is stopped. Press
      morning dose-3
      The current lock level will appear. (If the lock level is already LL0, press
      next-4
      to exit.)

    **Text Omitted**

    WARNING: Do not disclose to the patient the pump’s security codes or any other information that would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.

    Programming the Pump: General Instructions

    WARNING: System delivery inaccuracies beyond the stated accuracy may occur as a result of back pressure or fluid resistance, which depends upon temperature, medication viscosity, catheter size, extension set tubing, and orientation of the pump system.

    The procedure for changing a programmed setting is similar for most programming screens.

    • Make sure the pump is stopped and in lock level 0.
    • To begin programming, start at the main screen and press
      next-5
    • To change a setting, press
      up button-5
      or
      down button-6a
      until the desired setting appears. (Press and hold these keys to change values with increasing speed.)
    • Press
      enter clear-5
      within 25 seconds to confirm a change or the screen will revert to the previous setting.
    • If any key other than
      enter clear-5a
      is pressed, Value not saved will appear. Press
      next-6
      to return to the screen being programmed, scroll to the desired value, and press
      enter clear-7
    • Press
      next 5a
      to advance to the next screen.
    • To leave a setting unchanged, press
      next 0a
      to go to the next screen.

    Delivery Methods

    WARNING: Programming the pump at a delivery rate other than what is prescribed will cause over- or under-delivery of medication, which could compromise patient treatment. Please refer to the prescribing information for DUOPA for dosage and administration information.

    The CADD-Legacy® 1400 pump offers 3 methods of delivery:

    • Continuous rate
    • Extra dose
    • Morning dose

    The following graph illustrates the combined delivery methods. The continuous rate, extra dose, and morning dose are programmed as described in this section. Ranges and programming increments are listed in the Specifications in Section 5.

    combined delivery methods

    Programming Screens

    These are the programming screens for the CADD-Legacy® 1400 pump. Descriptions of the screens follow.

    Reservoir Volume (ml) resovoirvolumescreen
    Continuous Rate (ml/hr) contratescreen
    Extra Dose (ml) exdosescreen
    Given (ml) givenscreen

    Reservoir Volume

    NOTE: The default setting for Reservoir Volume is Not in Use. Programming a reservoir volume value is not required for general use, but is available at provider discretion.

    If you wish to use the reservoir volume feature, enter the volume of medication contained in the filled medication cassette reservoir. The reservoir volume value decreases as the pump delivers medication or as you prime the tubing. When you change the medication cassette reservoir, reset the reservoir volume value on this screen. If you do not wish to use the reservoir volume feature, scroll down to Not In Use (located before 1 and after 9999 in the range of values).

    The reservoir volume value could be set higher than the capacity of the medication cassette reservoir. Be sure to program the reservoir volume to reflect the actual volume in the reservoir.

    Continuous Rate

    Enter the continuous rate of medication delivery in ml/hr. The maximum rate is 20 ml/hr. If the prescription does not call for a continuous rate, enter zero.

    NOTE: If you intend to run the pump in lock level 1 so the continuous rate can be varied, you should enter the maximum allowable rate while programming in lock level 0. After programming, you may then change to lock level 1 and decrease the rate to its starting value. See Programming with Upper Limits, Adjusting Doses in LL1 at the end of Section 2.

    Extra Dose

    Enter the amount of medication to be delivered when the patient presses extra dose-3If the prescription does not call for an extra dose, enter zero.

    NOTE: If you intend to run the pump in lock level 1 so the extra dose can be varied, you should enter the maximum allowable dose while programming in lock level 0. After programming, you may then change to lock level 1 and decrease the dose to its starting value. See Programming with Upper Limits, Adjusting Doses in LL1 at the end of Section 2.

    Given

    This screen shows the total amount of medication delivered since the last time this value was cleared. The amount shown is rounded to the nearest 0.05 ml. If this value reaches 99999.95, it automatically returns to 0 and continues counting. When using the pump’s prime-2key, the amount of medication used is not included in the Given amount.

    Other Programming Information

    The morning dose should be programmed separately following programming of the above. Information on programming the morning dose can be found later in this section.

    Programming Delivery

    WARNING: Programming the pump at a delivery rate other than what is prescribed will cause over- or under-delivery of medication, which could compromise patient treatment. Please refer to the prescribing information for DUOPA for dosage and administration information.

    To program the pump, enter the prescribed values.

    1. Begin at the main screen.

    • Make sure the pump is in LL0.
    • Make sure STOPPED appears on the main screen.
    • Press
      next-9
      to begin.

    2. Enter the reservoir volume (optional – not required for general use).

    NOTE: The default setting for Reservoir Volume is Not in Use. Programming a reservoir volume value is not required for general use, but is available at provider discretion.

    • Press
      up button-6
      or
      down 0h
      to select the volume in the filled medication cassette reservoir. (If you do not wish to use the reservoir volume feature, scroll down to Not In Use located before 1 or after 9999.)
    • Press
      enter clear-8
    • Press
      next 0b

    3. Enter the continuous rate.

    • Press
      up button 0a
      or
      down button-7a
      to select the desired continuous rate.
    • Press
      enter clear-8a
    • Press
      next 9a

    4. Enter the extra dose amount.

    • Press
      up button 0b
      or
      down 0g
      to select the desired extra dose amount.
    • Press
      enter clear 0j
    • Press
      next 0c

    NOTE: If required, program the extra dose lockout time, as instructed in Section 4, Biomed Functions.

    5. Clear the amount given.

    • Press
      enter clear 0a
      if you wish to clear the amount given.
    • Press
      next 0d

    6. Review the program.

    Press next 0erepeatedly to review the programming screens. If you need to reprogram a setting, press next 0funtil the appropriate screen appears and change the setting as described in this section.

    Programming a Morning Dose

    To program a morning dose the pump must be running and a medication cassette reservoir must be attached.

    To program a morning dose

    1. Make sure the pump is running and in LL0 or LL1. Start the pump, if necessary.
      NOTE: In LL0, programming in the full range is possible. In LL1, you can program up to the LL0 value.
    2. Press
      morning dose-6
      The current morning dose value will appear.
      morningdosescreen
    3. Press
      up button 0c
      or
      down 0e
      to select the desired morning dose value.
    4. Press
      enter clear-12
      to enter the value into the pump’s memory. (If desired, press
      morning-dose-0e
      again to begin delivering the morning dose.)

    Once entered, the morning dose amount is retained in the pump’s memory. The patient can then press morn dose 6atwice to display and deliver the morning dose.

    NOTE: If required, program the morning dose lockout time, as instructed in Section 4, Biomed Functions.

    Removing a Medication Cassette Reservoir

    WARNING: Clamp the fluid path tubing and/or disconnect the tubing from the enteral access device before removing the medication cassette reservoir from the pump to prevent uncontrolled delivery of medication, which could compromise patient treatment.

    To remove the medication cassette reservoir from the pump

    1. Stop the pump.
    2. Close the tubing clamp. If necessary, disconnect the tubing from the enteral access device.
    3. Insert a coin into the slot in the cassette latch and turn it clockwise. The latch will pop out when you unlatch the cassette (the part of the medication cassette reservoir that attaches to the bottom of the pump).
    4. A continuous alarm will sound and the pump will display No Disposable, Clamp Tubing (the pump is not sensing proper cassette attachment). The alarm may be silenced by pressing
      stop start-4
      or
      next-16
    5. Remove the cassette hooks from the pump hinge pins.

    Attaching a Medication Cassette Reservoir

    Obtain a new, filled medication cassette reservoir.

    WARNING:
    • Use only approved DUOPA medication cassette reservoirs to maintain pump accuracy and assure proper pump operations.
    • Use only extension sets approved for use with DUOPA, paying particular attention to all warnings and cautions associated with their use.

    After attaching the medication cassette reservoir, proceed to the reservoir volume screen to reset the value for the volume, and then prime the tubing.

    To attach the medication cassette reservoir to the pump
    1. Clamp the tubing.

    2. Insert the cassette hooks into the hinge pins on the pump.

    3. Place the pump upright on a firm, flat surface. Press down so the cassette fits tightly against the pump.
    attachcassette1
    4. Insert a coin into the slot in the cassette latch, push in, and turn counterclockwise until the line on the latch lines up with the arrow on the side of the pump and you feel the latch click into place. attachcassette3
    WARNING: Attach the cassette properly. The cassette is the part of the medication cassette reservoir that attaches to the pump. A detached or improperly attached cassette could result in unintended delivery of medication, which could compromise patient treatment.
    5. Gently twist, push, and pull on the medication cassette reservoir to make sure it is firmly attached. If the cassette is not secure, repeat the procedure from step 1. attachcassette2

    Priming the Tubing and Connecting to the Patient

    WARNING: Do not prime the fluid path with the tubing connected to a patient as this could result in over-delivery of medication, which could compromise patient treatment.

    The pump must be stopped and in LL0 or LL1 in order to prime the fluid path. If the pump is in LL2, you cannot prime the fluid path.

    NOTE: If you are not changing the medication cassette reservoir but wish to prime the fluid path, you may follow the same procedure.

    1. Make sure the tubing is disconnected from the patient and the tubing clamp is open.
    2. Press and hold
      prime 0h
      You will hear a single beep, and the word Prime and 3 sets of dashes, each accompanied by a beep, will appear on the display.
    3. After Prime and 3 sets of dashes appear, release
      prime 0f
    4. Press and hold
      prime 0e
      again to fill the fluid path. The screen displays Priming . . . and you will hear a short beep each time the pump goes through a delivery cycle.

      NOTE: Medication delivered during priming is subtracted from the reservoir volume, but is not added to the given screen since this amount is not delivered to the patient.

    5. If the tubing is not yet fully primed, press and hold
      prime 0d
      again. If the tubing is primed, press
      next 16a
      to return to the main screen.

      NOTE: Each time you press and holdprime 0c you pump a maximum of 1 ml of medication into the tubing. The pumping action will stop automatically when 1 ml has been delivered. Releaseprime 0bif you finish priming the fluid path sooner. If the fluid path is not fully primed, repeat the above priming procedure.

    6. Connect the tubing to the patient’s enteral access device.
    7. Set the lock level for the patient (see Setting the Lock Level for the Patient in this section).

    Setting the Lock Level for the Patient

    The lock level must be changed to LL1 or LL2 to prevent the patient from having complete access to all programming and operating functions.

    NOTE: You may change the lock level at any time by stopping the pump and following the procedure below.

    To change the lock level

    **Text Omitted**

    WARNING: Do not disclose to the patient the pump’s security codes or any other information that would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.

    Programming with Upper Limits, Adjusting Doses in Lock Level 1

    If a prescription allows for the continuous rate, extra dose, or morning dose to be adjusted during the course of therapy, you may wish to operate the pump in LL1. Then, when necessary, you can adjust values up to the maximum value that was programmed in LL0.

    Programming the pump to use this feature

    1. During initial programming in LL0, enter the upper limit values for the continuous rate, extra dose and/or morning dose. (These will be the maximum values when the pump is in LL1.)
    2. After you are finished programming, change the lock level to LL1.
    3. Decrease the continuous rate, extra dose and/or morning dose to its starting value, then press
      enter clear0b

    Adjusting the rate or dose while the pump is in use

    • If it becomes necessary to increase or decrease the continuous rate, and/or extra dose during the course of therapy, stop the pump but remain in LL1.
    • To increase or decrease the morning dose, the pump must be in LL1, but it must remain running.
    1. To change the continuous rate or extra dose, press
      next-18
      until the continuous rate or extra dose screen appears.

      To change the morning dose, press morn dose 0b

    2. Press
      up button-9
      or
      down button-10a
      to select the desired value, then press
      enter clear 0c

      NOTE: You will not be able to adjust the continuous rate, extra dose, or morning dose beyond the value originally programmed in LL0.

    3. Restart the pump if appropriate.

    3.0 Operating the Pump

    Starting the Pump

    When you start the pump, programmed values will be automatically reviewed. Then medication delivery will begin as programmed, and RUN will appear on the main screen. If the pump will not start, a message will appear on the display. Refer to the Messages and Alarms Table in Section 5.

    CAUTION: Prior to starting medication delivery, inspect the fluid path for kinks, a closed clamp, or other obstruction. An undetected occlusion may result in under- or non-delivery and/or nuisance alarms.

    To start the pump

    1. Press and hold
      stop start-40

      Starting and 3 sets of dashes appear on the display; then the dashes disappear one-by-one, each accompanied by a single beep.

    2. Release
      stop start 0a
      after the last set of dashes disappears, and the pump beeps. All of the programming screens appear for your review one after the other.

    Stopping the Pump

    Stopping the pump stops delivery. When the pump is stopped, STOPPED will appear on the main screen, and you will hear 3 beeps every 5 minutes.

    To stop the pump

    1. Press and hold
      stop start 0b

      Stopping and 3 sets of dashes appear one-by-one on the pump’s display, each accompanied by a single beep.

    2. Release
      stop start 0c
      after the third set of dashes appears and the pump beeps.

    Turning the Pump On/Off

    When the pump is stopped, you may put the pump into a low power state by turning it off. The pump may be turned off when it is disconnected from the patient and it is going to be stored for short periods of time.

    CAUTION: Do not store the pump for prolonged periods of time with the batteries installed. Battery leakage could damage the pump.

    To turn the pump off

    1. Press and hold
      on off-3
      Turning off and 3 sets of dots will appear one-by-one on the pump’s display, each accompanied by a single beep.
    2. Release
      on off 0a
      The display turns off.

    To turn the pump on

    1. Press and hold
      on off 0b
      until the display turns on.
    2. Release
      on off 0c
      The pump will power up and automatically review all screens.

    Starting a Morning Dose

    A morning dose may be delivered in any lock level while the pump is running. It allows you to deliver a specified amount of medication, as a loading dose for example.

    If the patient attempts to deliver a morning dose during the lockout time, the pump will not deliver the dose. The lockout time is determined by the value entered in Morning Dose Lockout, in biomed functions. The extra dose lockout setting has no effect on morning dose frequency. A morning dose may be stopped in progress.

    NOTE: A morning dose cannot be started while an extra dose or another morning dose is in progress.

    To start a morning dose

    To program a morning dose, the pump must be running and a medication cassette reservoir must be attached.

    NOTE: Themorning dose-13key must be pressed twice for morning dose delivery to start.

    1. Make sure the pump is running (in any lock level). Start the pump if necessary.
    2. Press
      morn dose 0a

    The current morning dose value (or the default value of 0 ml) will appear UNLESS the morning dose is currently locked out (in which case the screen will not appear). If the desired morning dose amount appears in the display, pressmorn dose 13aagain to begin delivery.

    NOTE: If the desired morning dose amount does not appear in the display, program the desired morning dose amount as instructed in Section 2, Pump Setup and Programming.

    The screen will show the value decreasing as the morning dose is delivered.

    Starting an Extra Dose

    If an extra dose has been programmed, the patient may start an extra dose while the pump is running. The amount delivered is added to the amount provided by the continuous rate.

    If the patient attempts to deliver an extra dose during the lockout time, the pump will not deliver the dose. The lockout time is determined by the value entered in Extra Dose Lockout, in biomed functions.

    NOTE: An extra dose cannot be started while another extra dose or a morning dose is in progress.

    To start an extra dose

    1. Make sure the pump is running (in any lock level). Start the pump if necessary.
    2. Press
      extra dose-4
      Two beeps will sound and the pump will begin delivering the extra dose.

      As the extra dose is delivered, the main screen will show DOSE in place of RUN.

    Stopping an Extra Dose or Morning Dose

    An extra dose or morning dose can be stopped in progress. The pump may be in any lock level.

    To stop an extra dose or morning dose in progress

    • Press and hold
      stop start-9
      to stop the pump. All delivery is stopped, including the continuous rate.

    Resetting the Reservoir Volume

    NOTE: The default setting for Reservoir Volume is Not in Use. Programming a reservoir volume value is not required for general use, but is available at provider discretion.

    To reset the reservoir volume to the value programmed in LL0, the pump may be in any lock level.

    1. Stop the pump.
    2. Press
      next-19
      to display the reservoir volume screen.
    3. Press
      enter-clear-17
      to reset the volume to the programmed value.

    4.0 Biomed Functions

    Overview: Accessing the Biomed Functions and Programming the Lockouts

    The biomed functions are pump configurations that are less frequently changed. The biomed functions are accessible only when the pump is stopped and in lock level 0 (LL0).

    To access the Biomed Functions

    **Text Omitted**

    WARNING: Do not disclose to the patient the pump’s security codes or any other information that would allow the patient complete access to all programming and operating functions. Improper programming could compromise patient treatment.

    4. Pressnext 0gto select the setting you wish to view or change, then follow the instructions in this section for the appropriate screen.

    NOTE: To leave a biomed function setting unchanged, press next 0h

    5. To exit the biomed functions, pressnext 0iuntil you get to the screen that reads, NEXT for Biomed, ENTER for Main.

    6. Pressenter clear 0dto return to the main screen.

    Extra Dose Lockout

    The extra dose lockout time determines how often a patient can receive an extra dose of medication. The lockout time is the minimum amount of time which must elapse between the start of one dose and the start of the next.

    To program an extra dose lockout time
    1. With the pump stopped and in LL0, access biomed functions. (Refer to the beginning of the Biomed Functions section for instructions on how to access biomed functions.)
    2. Pressnext-button-0tuntil Extra Dose appears.

    3. Pressup button-14ordown button-15ato scroll to the desired lockout time. The default lockout time is 1 hour.

    4. Pressenter-clear-21to enter the value.


    extradosescreen
    CAUTION: When you enter a new value, any lockout time already in effect will be cleared. An extra dose could be requested and delivered immediately upon starting the pump, which may result in over-delivery of medication.

    Morning Dose Lockout

    The morning dose lockout time determines how often a patient can receive a morning dose. The lockout time is the minimum amount of time which must elapse between the start of one dose and the start of the next.

    To program a morning dose lockout time
    1. With the pump stopped and in LL0, access biomed functions. (Refer to the beginning of the Biomed Functions section for instructions on how to access biomed functions.)
    2. Pressnext 0juntil Morning Dose appears.

    3. Pressup button 0dordown 0fto scroll to the desired lockout time.

    4. Pressenter clear 0eto enter the value.








    morningdosescreen
    CAUTION: When you enter a new value, any lockout time already in effect will be cleared. A morning dose could be requested and delivered immediately upon starting the pump, which may result in over-delivery of medication.

    Upstream Occlusion Sensor On/Off

    The upstream occlusion sensor can be set to On or Off. If this screen is set to On, and an occlusion in the medication cassette reservoir is detected, an alarm will sound, delivery will stop, and the display will show Upstream Occlusion.

    CAUTION: When the upstream occlusion sensor is turned off, the pump will not detect occlusions in the medication cassette reservoir. Periodically inspect the medication cassette reservoir for decreasing volume. Undetected occlusions could result in under- or non-delivery of medication.
    1. With the pump stopped and in LL0, access biomed functions. (Refer to the beginning of the Biomed Functions section for instructions on how to access biomed functions.)
    2. Pressnext 0kuntil Upstream Sensor appears.

    3. Pressup button 0eordown 0dto select Off or On.

    4. Pressenter clear 0fto enter the change.
    upsensorscreen

    5.0 Reference

    Messages and Alarms, Alphabetical List

    Messages and Alarms Description / Corrective Action
    [No message]
    Two-tone alarm
    With no AC adapter attached, the batteries have been removed while the pump is running. The pump is now stopped and unpowered. Install batteries to silence the alarm.
    OR
    Batteries were removed within approximately 15 seconds after stopping the pump. Install new batteries to silence the alarm, if desired. Otherwise, the alarm will stop within a short period of time.
    [Screen displays current pump status]
    Two-beeps (long-short)
    The medication cassette reservoir is not aligned with the pump or medication is not flowing from the medication bag inside the reservoir to the pumping mechanism.
    Pressstop start-10 or next 0lto silence the alarm. The pump continues to run. Make sure the medication cassette reservoir is properly aligned with the pump and medication is flowing from the medication bag to the pumping mechanism. Very cold or extremely thick medication may cause this alarm as well. Allow the medication cassette reservoir to thaw to room temperature before attaching to the pump.
    Battery Depleted
    Two-tone alarm
    The battery power is too low to operate the pump. The pump is now stopped.
    • Change the batteries immediately.
    • Press and holdstop start 0e to restart the pump.
    Battery Removed
    Pump won’t run

    Two-tone alarm
    With the AC adapter attached, the AA batteries have been removed while the pump is running, or you have tried to start the pump with depleted batteries. The pump is now stopped. Pressstop start 0f or next 26ato silence the alarm. Reinstall batteries or install new batteries. Press and holdstop start 0g to restart the pump.
    Error
    Two-tone alarm
    An error has occurred. Remove the pump from service and contact Smiths Medical to return the pump for service.
    High Pressure
    Two-tone alarm
    The pump has detected high pressure, which may be resulting from a downstream blockage, kink in the fluid path, or a closed clamp. Remove the occlusion to resume operation. Or, pressstop start 0hor next 0mto stop the pump and silence the alarm for 2 minutes, then remove the occlusion and restart the pump.
    Key pressed,
    Please release

    Two-tone alarm
    If a key is being pressed, stop pressing it. If the alarm persists, close the tubing clamp and remove the pump from use. Contact Smiths Medical to return the pump for service.
    LowBat
    Three two-tone beeps every 5 minutes
    The batteries are low, but the pump is still operable.
    • Change the batteries soon.
    Motor Locked, remove all power
    Two-tone alarm
    Batteries are depleted and the pump was powered up with the AC adapter. Install new AA batteries, reconnect the AC adapter, and restart the pump.
    No Disposable,
    Clamp Tubing

    Two-tone alarm
    The disposable (medication cassette reservoir) was removed. The pump is not sensing proper cassette attachment. Clamp the tubing and disconnect from the enteral access device. A medication cassette reservoir must be properly attached in order for the pump to run. Pressstop-start-0oor next 0nto silence the alarm.
    No Disposable,
    Pump won’t run

    Two-tone alarm
    You have tried to start the pump without a disposable (medication cassette reservoir) attached. A medication cassette reservoir must be properly attached in order for the pump to run. Pressstop start 0i or next 0oto silence the alarm.
    Power lost while pump was on
    Two-tone alarm
    The pump was running when power was removed. Stop the pump before changing the batteries or removing the power source. Pressstop start 0jor next 0pto silence the alarm.
    Programming Incomplete
    Two-tone alarm when starting the pump
    A rate or dose must be programmed to start the pump. Pressstop start 0kor next 0qto silence the alarm.
    Reservoir Volume Empty
    Two-tone alarm
    The reservoir volume has reached 0.0 ml. Pressstop start 0lor next 0rto silence the alarm. Then install a new medication cassette reservoir if appropriate and reset the reservoir volume.
    RUN
    ResVol Low

    Three single beeps
    The reservoir volume is low. Change the medication cassette reservoir soon. See Reservoir Volume Alarm in Section 1 for further details.
    Service Due
    Two-tone alarm
    The pump is functional, but is due for service based on clock battery age or total motor revolutions. This screen appears in LL0 for 60 days and then in all lock levels until returned for service.
    Upstream Occlusion
    Two-tone alarm
    If the upstream occlusion sensor is set to On and an occlusion in the medication cassette reservoir is detected, the upstream occlusion alarm will sound. Pressstop start 0mor next 0sto stop the pump and silence the alarm for 2 minutes, then remove the occlusion and restart the pump. You may have to detach the cassette from the pump, then reattach it.
    Value not saved A value was not saved by pressingenter clear-24Pressnext 0tto resume programming. Verify all programming screens before moving to the next screen or starting the pump.
    What if the pump is dropped or hit?
    Immediately do the following:
    • Check the cassette latch on the side of the pump and make sure the line on the latch lines up with the arrow on the side of the pump.
    droppedorhit1
    • Gently twist, push, and pull on the medication cassette reservoir to make sure it is still firmly attached.
    droppedorhit2
    • Check the battery door to make sure it is still firmly attached.

    If the medication cassette reservoir or the battery door is loose or damaged, do not use the pump. Immediately stop the pump, close the tubing clamp, and contact Smiths Medical.

    WARNING: If the pump is dropped or hit, inspect the pump for damage. Do not use a pump that is damaged or is not functioning properly, as this could compromise patient treatment.
    • If the pump is accidentally dropped in water, retrieve it quickly, dry it off with a towel, and contact Smiths Medical.

    Cleaning the Pump and Accessories

    CAUTION:
    • Do not immerse the pump in cleaning fluid or water. Do not allow solution to soak into the pump, accumulate on the keypad, or enter the battery compartment. Moisture buildup inside the pump may damage the pump.
    • Do not clean the pump with acetone, other plastic solvents, or abrasive cleaners, as damage to the pump may occur.

    NOTE: Refer to the Instructions for Use for each accessory before proceeding with cleaning.

    The following solutions may be used to clean the pump and accessories, unless otherwise specified:

    • Soap solution
    • Benzalkonium chloride concentrate (0.13%)
    • Glutaral concentrate, USP (2%)
    • 10% solution of household bleach (one part household bleach to 9 parts water)
    • Alcohol, USP (93%)
    • Isopropyl Alcohol, USP (99%)
    • Chlorhexidine gluconate (4%)
    • PDI Super Sani-Cloth®
    • MadaCide, Mada Medical
    1. Dampen a soft, lint-free cloth with cleaning solution. Apply the solution to the exterior surface of the pump (per manufacturer’s instructions). Do not allow the solution to soak into the pump or accessory.
    2. Wipe the entire surface dry with another soft, lint-free cloth. Allow the pump to dry completely before use.

    Cleaning the Battery Contacts

    Routinely clean the battery contacts, possibly as part of the preventative maintenance cycle, to remove buildup of foreign material on the contacts.

    Use the following to clean the battery contacts:

    • Cotton swab wetted with Isopropyl Alcohol (70% minimum)

      NOTE: Do not use an alcohol formulation that contains components other than alcohol and water.

      OR
    • Pre-moistened alcohol swab
    1. Using a swab wetted with alcohol, rub the entire battery contact for a minimum of 10 back and forth cycles (20 total wipes over the contact).
    2. Using a clean surface of the swab, repeat process for second battery contact.
    3. Using a clean swab wetted with alcohol, rub each battery contact again, a minimum of 4 back and forth cycles (8 total wipes over the contact).
    4. Allow the contacts to dry completely before use.

    Exposure to Radiation, Ultrasound, Magnetic Resonance Imaging (MRI), or Use near ECG Equipment

    CAUTION:
    • Do not expose the pump to therapeutic levels of ionizing radiation as permanent damage to the pump’s electronic circuitry may occur. The best procedure to follow is to remove the pump from the patient during therapeutic radiation sessions. If the pump must remain in the vicinity during a therapy session, it should be shielded, and its ability to function properly should be confirmed following treatment.
    • Do not expose the pump directly to ultrasound, as permanent damage to the electronic circuitry may occur.
    • Do not use the pump in the vicinity of magnetic resonance imaging (MRI) equipment as magnetic fields may adversely affect the operation of the pump. Remove the pump from the patient during MRI procedures and keep it at a safe distance from magnetic energy.
    • This pump may interfere with ECG equipment. Monitor ECG equipment carefully when using this pump.

    Continuous Rate Scroll Ranges

    Starting Value Increment Maximum
    0.0 ml/hr 0.1 ml/hr 20.0 ml/hr

    Extra Dose, Morning Dose Scroll Ranges

    Extra Dose
    increment max.
    0.1 ml 9.9 ml
    Morning Dose
    increment max.
    0.1 ml 20 ml

    Technical Description

    Standards used in Development of the Pump
    The following standards were used in whole or part in the development of the pump:
    IEC 60601-1 (1988), (2nd Edition, 1988) Medical Electrical Equipment, Part 1: General Requirements for Safety. Amendment 1 (1991), Amendment 2 (1995).
    EN 60601-1 (1990), Medical Electrical Equipment, Part 1: General Requirements for Safety. Amendment A1 (1993), Amendment A13 (1996), Amendment A2 (1995).
    IEC 60601-1-2 (2007), Medical Electrical Equipment, Part 1-2: General Requirements for Safety – Collateral Standard: Electromagnetic Compatibility – Requirements and Tests.
    EN 60601-1-2 (2007), Medical Electrical Equipment, Part 1-2: General Requirements for Safety – Collateral Standard: Electromagnetic Compatibility – Requirements and Tests.
    The following are reference test methods applied to IEC/EN 60601-1-2:
      IEC/EN 61000-4-2, Electromagnetic Compatibility (EMC), Part 4: Testing and measurement techniques. Section 2: Electrostatic Discharge immunity test. Basic EMC Publication.
      IEC/EN 61000-4-3, Electromagnetic Compatibility (EMC), Part 4: Testing and measurement techniques. Section 3: Radiated, radio frequency, electromagnetic fields immunity test. Basic EMC Publication.
      IEC/EN 61000-4-4, Electromagnetic Compatibility (EMC), Part 4: Testing and measurement techniques. Section 4: Electrical fast transients/bursts immunity test. Basic EMC Publication.
      IEC/EN 61000-4-5, Electromagnetic Compatibility (EMC), Part 4: Testing and measurement techniques. Section 5: Surge immunity test. Basic EMC Publication.
      IEC/EN 61000-4-8, Electromagnetic Compatibility (EMC), Part 4: Testing and measurement techniques. Section 8: Power frequency magnetic field immunity test.
      IEC/EN 61000-4-11, Electromagnetic compatibility (EMC) - Part 4: Testing and measuring techniques - Section 11: Voltage dips, short interruptions and voltage variations immunity tests.
    IEC 60601-2-24 (1998), Medical Electrical Equipment, Part 2-24: Particular Requirements for Safety of Infusion Pumps and Controllers.
    EN 60601-2-24 (1998), Medical Electrical Equipment, Part 2-24: Particular Requirements for Safety of Infusion Pumps and Controllers.
    IEC 60601-1-4 (2000), Medical Electrical Equipment, Part 1: General Requirements for Safety – Collateral Standard: Programmable electrical medical systems.
    EN 60601-1-4 (1996), Medical Electrical Equipment, Part 1-4: General Requirements for Safety – Collateral Standard: Programmable electrical medical systems. Amendment A1: 1999.
    EN 980 (2008), Graphical symbols for use in the labeling of medical devices.
    FCC Part 15 Subpart B, Radiofrequency Devices, Unintentional Radiators.
    RTCA/DO -160C, Radiated Emissions Only, Category A & Z Limit.
    EN 55011 (2007), Limits and Methods of Measurement of Radio Interference Characteristics of Industrial, Scientific and Medical (ISM) Equipment. Amendment A2: 2007. (Equivalent to CISPR 11: 2003 + Amendment A2: 2006).
    CISPR11 (2009), Limits and methods of measurement of electromagnetic disturbance characteristics of industrial, scientific and medical (ISM) radio frequency equipment. Amendment 1 (1996) Amendment 2 (1996).
      For CISPR11 tests, the pump was fitted with an administration set with its inlet connected to a 250 ml bag and its outlet routed back to the bag forming a closed loop system. A total of 6 feet of tubing was used to form the closed loop.

    Specifications (Nominal)

    1Therapy delivery accuracy: program to deliver a 10 ml morning dose with a 5 ml/hr continuous rate and three 3 ml extra doses, with a total of 100 ml of medication delivered. Pumps were evaluated in latch down, upside down, and horizontal position. The medication cassette with DUOPA (carbidopa and levodopa) enteral suspension is initially cold (approx. 2°C). Remove cassette from refrigerator, wait 20 minutes, then conduct the test at nominal temperature.2
    2At nominal temperature (23°C ± 5°C)
    3An additional -4% change may be seen when cassette starting temperature is 2°C and placed at room temperature (23°C ± 5°C) for 20 minutes prior to use.
    General Pump Specifications
    Resolution medication cassette reservoir: 0.05 ml per pump activation nominal
    Size 4.1 cm × 9.5 cm × 11.2 cm [1.6 in. × 3.8 in. × 4.4 in.] excluding medication cassette reservoir
    Weight 392 g [13.8 oz.] including 2 AA batteries, empty 100 ml medication cassette reservoir, excluding other accessories
    Classification (IEC 60601-1) CF type cf-2Class II classii
    Moisture protection Splashproof (IPX4)
    Pump alarms Low battery power; depleted battery power; battery dislodged; pump stopped; pump fault; low reservoir volume; high pressure; disposable not attached when run attempted; motor locked; upstream occlusion; reservoir volume empty; program incomplete; remote dose cord removed; key stuck; disposable detached.
    Maximum infusion pressure 40 psi [2.76 bar]
    Maximum time to occlusion alarm (actual test data) DUOPA (carbidopa and levodopa) enteral suspension: 10 hours 30 minutes
    Bolus volume at occlusion alarm pressure 0.05 ml resolution medication cassette reservoir: <1.1 ml
    Power sources AC adapter; Two AA alkaline batteries
    Battery life The expected life of 2 AA batteries is 100 hours at 100 ml/16 hours, or approximately 14 days at 10 ml/day (nominal). This estimate is based on laboratory tests conducted at room temperature using two new batteries. Actual battery life will vary depending on the brand of battery, battery shelf life, temperature conditions, and delivery rate. It is recommended that two new AA batteries be kept available for replacement if necessary.

    An internal battery powers the clock. When it is depleted, it cannot reliably maintain the clock time. This battery must be replaced by the manufacturer. The internal battery has an expected life of 5 years.
    System operating temperature 2°C to 40°C (36°F to 104°F)
    System storage and transportation temperature -20°C to 60°C (-4°F to 140°F)
    When shipping, use pump case.
    System delivery accuracy (DUOPA [carbidopa and levodopa] enteral suspension):
    Therapy1 ±10%
    Continuous rate2 ±10% @ flow rates 0.4 ml/hr to 20 ml/hr
    Extra dose2 ±10%
    Morning dose2,3 ±10%
    Accessories: 100 ml medication cassette reservoir with 36” 0.10” I.D. tube
    WARNING: System delivery inaccuracies beyond the stated accuracy may occur as a result of back pressure or fluid resistance, which depends upon temperature, medication viscosity, catheter size, extension set tubing, flow rate, and orientation of the pump system.
    System definition System is defined as a CADD-Legacy® 1400 pump with attached medication cassette reservoir supplied by AbbVie
    High pressure alarm 26 ± 14 psi [1.79 ± 0.97 bar]
    Maximum volume infused under single fault condition medication cassette reservoir: 0.2 ml.
    Delivery rate during priming Approx. 125 ml/hr
    Delivery Specifications
    Reservoir volume 1 to 9999 or Not In Use; programmable in 1 ml increments, displayed in 0.1 ml increments Default: Not In Use
    Continuous rate 0 to 20 ml/hr in 0.1 ml/hr increments
    Default: 0.1 ml/hr
    Extra dose 0 to 9.9 ml in 0.1 ml increments
    Delivery rate (continuous rate + extra dose): 40 ml/hr
    Default: 0 ml
    Given 0 to 99999.95 in 0.05 unit increments
    Morning dose 0 to 20.00 ml in 0.1 ml increments
    Delivery rate (continuous rate + morning dose):
    40 ml/hr
    Default: 0 ml
    Biomed Functions
    Extra dose lockout 15 minutes to 24 hours in 15 minute increments
    Default: 1 hour
    Morning dose lockout 1 to 24 hours in 1 hour increments Default: 20 hours
    Upstream sensor Off
    On
    Default: Off

    Accuracy Test Results

    The following graphs are designed to show flow accuracy of the infusion system plotted against given time periods. The medication cassette reservoir used for flow accuracy tests was supplied by AbbVie.

    Flow rate immediately following startup
    Time Interval: 0.5 min
    Total Time: 120 min
    Programmed Rate: 5 ml/hr
    Reservoir Used: 100 ml medication cassette reservoir
    immediateflowrate
    Short term flow rate error
    Programmed Rate: 5 ml/hr
    Average Flow Rate: 4.76 ml/hr
    Mean Flow Error: –4.65%
    Reservoir Used: 100 ml medication cassette reservoir
    flowrateerror

    Electromagnetic Emissions and Immunity Declarations

    Electromagnetic emissions declaration
    The Pump is intended for use in the electromagnetic environment specified below. The customer or the user of the Pump should assure that it is used in such an environment.
    Emissions test Compliance Electromagnetic environment – guidance
    RF emissions, CISPR 11 Group 1 The Pump uses RF energy only for its internal function. Therefore, its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment.
    RF emissions, CISPR 11 Class B The Pump is suitable for use in all establishments, including domestic establishments and those directly connected to the public low-voltage power supply network that supplies buildings used for domestic purposes.
    Harmonic emissions
    IEC 61000-3-2
    Not applicable
    Voltage fluctuations/
    flicker emissions
    IEC 61000-3-3
    Not applicable

    Compliance using:

    1. 115VAC/60HZ to 8VDC Power Adapter (US) with a cord length of 274 ± 10 cm (108 ± 4 in).
    2. Remote Dose Cord with a length of 152 ± 5 cm (60 ± 2 in).
    WARNING:
    • The Pump should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the user should verify normal operation of the pump in the configuration in which it is to be used.
    • The use of power supplies and a remote dose cord other than those listed in the electromagnetic emissions declaration may result in increased emissions or decreased immunity of the Pump.
    Electromagnetic immunity declaration
    The Pump is intended for use in the electromagnetic environment specified below. The customer or the user of the Pump should assure that it is used in such an environment.
    Immunity test IEC 60601
    test level
    Compliance
    level
    Electromagnetic environment – guidance

    Electrostatic discharge (ESD)

    IEC 61000-4-2

    ±8 kV contact

    ±15 kV air

    ±8 kV contact

    ±15 kV air

    Floors should be wood, concrete or ceramic tile. If floors are covered with synthetic material, the relative humidity should be at least 30%.

    Electrical fast transient/burst

    IEC 61000-4-4

    ±2 kV for power supply lines
    ±1 kV for input/output lines
    ±2 kV for power supply lines
    Not applicable
    Mains power quality should be that of a typical commercial or hospital environment.

    Surge

    IEC 61000-4-5

    ±1 kV differential mode
    ±2 kV common mode
    ±1 kV differential mode
    ±2 kV common mode
    Mains power quality should be that of a typical commercial or hospital environment.

    Voltage dips, short interruptions and voltage variations on power supply input lines

    IEC 61000-4-11

    <5 % UT (>95 % dip in UT) for 0,5 cycle

    40 % UT (60 % dip in UT) for 5 cycles

    70 % UT (30 % dip in UT) for 25 cycles

    <5 % UT (>95 % dip in UT) for 5 sec

    <5 % UT (>95 % dip in UT) for 0,5 cycle

    40 % UT (60 % dip in UT) for 5 cycles

    70 % UT (30 % dip in UT) for 25 cycles

    <5 % UT (>95 % dip in UT) for 5 sec

    Mains power quality should be that of a typical commercial or hospital environment. If the user of the Pump requires continued operation during power mains interruptions, it is recommended that the Pump be powered from an uninterruptible power supply or a battery.
    Power frequency 50/60 Hz) magnetic field
    IEC 61000-4-8
    3 A/m

    400 A/m

    (IEC 60601-2-24)

    Power frequency magnetic fields should be at levels characteristic of a typical location in a typical commercial or hospital environment.
    NOTE: UT is the a.c. mains voltage prior to application of the test level.
    Electromagnetic immunity declaration
    The Pump is intended for use in the electromagnetic environment specified below. The customer or the user of the Pump should assure that it is used in such an environment.
    Immunity test IEC 60601
    test level
    Compliance
    level
    Electromagnetic environment – guidance
          Portable and mobile RF communications equipment should be used no closer to any part of the Pump, including cables, than the recommended separation distance calculated from the equation applicable to the frequency of the transmitter.

    Conducted RF

    IEC 61000-4-6

    3 Vrms
    150 kHz to
    80 MHz
    10 Vrms

    Recommended separation distance

    d=0.27*P1/2

    Radiated RF
    IEC 61000-4-3
    3 V/m
    80 MHz to
    2,5 GHz
    10 V/m

    d=0.27*P1/2 80MHz to 800 MHz

    d=0.54*P1/2 800MHz to 2,5 GHz

    Where P is the maximum output power rating of the transmitter in watts (W) according to the transmitter manufacturer and d is the recommended separation distance in meters (m).

    Field strengths from fixed RF transmitters, as determined by an electromagnetic site survey,a should be less than the compliance level in each frequency range.b

    Interference may occur in the vicinity of equipment marked with the following symbol: interferencesymbol

    NOTE 1: At 80 MHz and 800 MHz, the higher frequency range applies.
    NOTE 2: These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.
    aField strengths from fixed transmitters, such as base stations for radio (cellular/cordless) telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast cannot be predicted theoretically with accuracy. To assess the electromagnetic environment due to fixed RF transmitters, an electromagnetic site survey should be considered. If the measured field strength in the location in which the Pump is used exceeds the applicable RF compliance level above, the Pump should be observed to verify normal operation. If abnormal performance is observed, additional measures may be necessary, such as reorienting or relocating the Pump.
    bOver the frequency range 150 kHz to 80 MHz, field strengths should be less than 10 V/m.
    Recommended separation distances between portable and mobile RF communications equipment and the Pump
    The Pump is intended for use in an electromagnetic environment in which radiated RF disturbances are controlled. The customer or the user of the Pump can help prevent electromagnetic interference by maintaining a minimum distance between portable and mobile RF communications equipment (transmitters) and the Pump as recommended below, according to the maximum output power of the communications equipment.

    Rated maximum output power of transmitter

    Separation distance according to frequency of transmitter

    m

    W

    150 kHz to 80 MHz

    d=0.27*P1/2

    80 MHz to 800 MHz

    d=0.27*P1/2

    800 MHz to 2,5 GHz

    d=0.54*P1/2

    0.01 0.03 0.03 0.05
    0.1 0.09 0.09 0.17
    1 0.27 0.27 0.54
    10 0.85 0.85 1.7
    100 2.7 2.7 5.4
    For transmitters rated at a maximum output power not listed above, the recommended separation distance d in meters (m) can be determined using the equation applicable to the frequency of the transmitter, where P is the maximum output power rating of the transmitter in watts (W) according to the transmitter manufacturer.
    NOTE 1: At 80 MHz and 800 MHz, the separation distance for the higher frequency range applies.
    NOTE 2: These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.

    Safety Features and Fault Detection

    Hardware Safety Features

    Key hardware safety features include a watchdog timer circuit, motor driver and motor watchdog circuits, and a voltage detector circuit. Each safety circuit performs a unique function to insure the overall safety of the device.

    Watchdog Timer Circuit

    The microprocessor must send an appropriate signal to the watchdog circuit at least once per second. If the microprocessor does not, the watchdog circuit will time out and shut down the pump controller.

    Watchdog timer circuitry is provided to monitor the status of the microprocessor and disable the motor and enable the audible alarm if the microprocessor fails to function properly. The microprocessor must strobe the watchdog circuit at least once every second in order to prevent the watchdog from performing its reset function. The reset output from the watchdog circuit is a pulse output. This acts to “jump startˮ the microprocessor. This unique feature allows the microprocessor to test the watchdog circuit on every power-up.

    By setting a flag in the memory and not strobing the watchdog, the microprocessor can force a watchdog time-out. After being reset, the microprocessor checks the status flag to see if this was a time-out test. If so, the microprocessor continues normal power-up activities. If the reset occurred when the microprocessor was not expecting it, the microprocessor traps the event, sounds the audible alarm and displays an error message on the LCD.

    Motor Driver/Motor Watchdog Circuit

    Motor drive circuitry is composed of a series of power FET transistors, passive components, and 2 voltage comparators. Built into the motor drive circuitry is an RC timer which times how long the motor runs each time it is turned on. If the motor runs for more than an average of 3 seconds, the circuit will time out and disable the motor. A unique feature of this circuit is that control lines to and from the microprocessor circuit allow the microprocessor to perform a complete functional test of the motor drive circuit without running the motor. The microprocessor performs this test function every several minutes to assure its continued functionality. An input from the watchdog circuit prevents motor operation if the watchdog timer expires. The software verifies this function during the watchdog test described above.

    Voltage Detector Circuit

    Low voltage detection is performed by part of the watchdog circuit and by the microprocessor via software. Three low voltage levels are detected. The first 2 levels are detected by software and the third by hardware. The first level to be reached is the low battery warning threshold which occurs when the battery voltage decays to a nominal value of 2.4 volts when the motor is off or 1.8 volts when the motor is active. An analog to digital converter (ADC) built into the microprocessor allows the microprocessor, via software, to monitor the battery voltage. At the low battery warning threshold, the microprocessor enables a periodic series of beeps and displays a low battery warning message on the LCD. As the voltage operating the motor reaches a nominal value of 4.75 volts, the software disables delivery, places a battery depleted message on the LCD, and enables a constant two tone audible alarm. When the battery voltage decays to a nominal value of 1.0 volts, a hardware reset circuit is triggered which places the microprocessor in reset. This prevents ambiguous microprocessor operation when the battery voltage continues to decay. The hardware reset continues until the battery is completely discharged or until it is removed. Once the pump controller goes into low battery shutdown, only replacing the depleted batteries with new ones will clear the condition.

    Software Safety Features

    Hardware-related Software Safety Features

    Program Memory Check

    At power up and at regular intervals thereafter, the program memory is tested by calculating a cyclic redundancy code (CRC) on the program and then comparing it with the CRC stored with the program.

    If the stored and calculated CRCs do not match, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    RAM Memory Check

    At power up, the random access memory is checked. A series of bit patterns is written to and read from each address in the RAM. If the read data is different from the written data, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Motor Circuit Check

    At power up and at regular intervals thereafter, the motor circuit is checked to ensure that no power is being applied to the motor unless the motor is actually on. If the software detects power being applied to the motor at any other time, it will sound a continuous two-tone audible alarm and will no longer attempt to deliver medication. During every pump activation, the software checks to see whether the motor completes one activation. If the motor fails to turn, or fails to complete a cycle, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Keyboard Encoder Check

    Every time the software receives data from the keyboard encoder, it is checked. If the data is not a valid key press, the software will disregard the key press. The keyboard is designed with redundant switches for prime 0a, extra dose 0a, and stop start 0n. The software must detect that both switches are activated before taking any action.

    Data Handling Software Safety Features

    Data Stored in RAM

    Before use, data associated with delivery and stored in RAM is tested by calculating a CRC on the data and then comparing it with the CRC stored with the data. If the stored and calculated CRCs do not match, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Data Stored in EEPROM

    Before use, data associated with delivery and stored in EEPROM is tested by calculating a CRC on the data and then comparing it with the CRC stored with the data. If the stored and calculated CRCs do not match, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Data Stored in NOVRAM

    Before use, data associated with delivery and stored in NOVRAM is tested by calculating a CRC on the data and then comparing it with the CRC stored with the data. If the stored and calculated CRCs do not match, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Data Used in Calculations

    Calculations on data used in some way to control the delivery of medication are performed redundantly.

    The two calculated values are then compared. If the two values do not match, the software will display a system fault screen, turn on a continuous two-tone audible alarm, and stop all medication delivery.

    Timer Data Registers

    The data in the real time clock is checked at regular intervals. If the data is not reasonable, the software will turn on a continuous two-tone audible alarm and stop all medication delivery.

    Annual Functional Inspection

    Smiths Medical recommends annual functional inspections and tests on the CADD-Legacy® 1400 pump. Contact Smiths Medical to coordinate return and inspection of the pump.

    CAUTION: CADD-Legacy® 1400 pumps are sealed units. A broken or damaged seal will, therefore, be considered conclusive evidence that the pump has been misused and/or altered, which voids any and all warranties. All service and repair of CADD-Legacy® 1400 pumps must be performed by Smiths Medical or its authorized agents.

    Collect Separately

    This product contains electronic and other components (such as batteries) that may contain materials which, if disposed of with general household waste, could be damaging to the environment.

    In accordance with Directive 2002/96/EC Waste Electrical and Electronic Equipment, Smiths Medical requires that residents of the European Union return this product for proper disposal at the end of its useful life.

    If you are unsure of the proper disposal method, contact your local distributor for specific disposal instructions.

    WARNING: There are potential health hazards associated with improper disposal of batteries, electronics, and contaminated (used) reservoirs and extension sets. Dispose of used batteries, reservoirs, extension sets and other used accessories, or a pump that has reached the end of its useful life, in an environmentally safe manner, and according to any regulations that may apply.

    Limited Warranty

    Smiths Medical ASD, Inc. (the “Manufacturer”) warrants to the Original Purchaser that the infusion pump (the “Pump”), not including accessories, shall be free from defects in materials and workmanship under normal use, if used in accordance with this Operator’s Manual, for a period of one year from the actual date of sale to the Original Purchaser. THERE ARE NO OTHER WARRANTIES.

    This warranty does not cover normal wear and tear and maintenance items, and specifically excludes batteries, administration sets, extension sets or any other accessory items or equipment used with the Pump.

    Subject to the conditions of and upon compliance with this Limited Warranty, the Manufacturer will repair or replace at its option without charge (except for a minimal charge for postage and handling) any Pump (not including accessories) which is defective if a claim is made during such one-year period.

    The following conditions, procedures, and limitations apply to the Manufacturer’s obligation under this warranty:

    A. Parties Covered by this Warranty: This warranty extends only to the Original Purchaser of the Pump. This warranty does not extend to subsequent purchasers. The Original Purchaser may be a patient, medical personnel, a hospital, or institution which purchases the Pump for treatment of patients. The Original Purchaser should retain the invoice or sales receipt as proof as to the actual date of purchase.

    B. Warranty Performance Procedure: Notice of the claimed defect must be made in writing or by ­telephone to the Manufacturer as follows: Smiths Medical ASD, Inc. 1265 Grey Fox Road, St. Paul MN 55112 USA, 1 800.258.5361 (USA). Notice to the Manufacturer must include date of purchase, model and serial number, and a description of the claimed defect in sufficient detail to allow the Manufacturer to determine and facilitate any repairs which may be necessary. AUTHORIZATION MUST BE OBTAINED PRIOR TO RETURNING THE PUMP. If authorized, the Pump must be properly and carefully packaged and returned to the Manufacturer, postage prepaid. Any loss or damage during shipment is at the risk of the sender.

    C. Conditions of Warranty: The warranty is void if the Pump has been 1) repaired by someone other than the Manufacturer or its authorized agent; 2) altered so that its stability or reliability is affected; 3) misused; or, 4) damaged by negligence or accident. Misuse includes, but is not limited to, use not in compliance with the Operator’s Manual or use with nonapproved accessories. The Pump is a sealed unit, and the fact that the seal has been broken will be considered conclusive evidence that the Pump has been altered or misused. Removal or damage to the Pump’s serial number will invalidate this warranty.

    D. Limitations and Exclusions: Repair or replacement of the Pump or any component part thereof is the EXCLUSIVE remedy offered by the Manufacturer. The following exclusions and limitations shall apply:

    1. No agent, representative, or employee of the Manufacturer has authority to bind the Manufacturer to any representation or warranty, expressed or implied.
    2. THERE IS NO WARRANTY OF MERCHANTABILITY OR FITNESS OR USE OF THE PUMP FOR ANY PARTICULAR PURPOSE.
    3. The Pump can only be used under the supervision of medical personnel whose skill and judgment determine the suitability of the Pump for any particular medical treatment.
    4. All recommendations, information, and descriptive literature supplied by the Manufacturer or its agents are believed to be accurate and reliable, but do not constitute warranties.

    E. Computer Program License:

    1. The Pump is intended to be used in conjunction with a particular Licensed Computer Program supplied by Manufacturer and use of any other program or unauthorized modification of a Licensed Computer Program shall void Manufacturer’s warranty as set forth above.
    2. The Original Purchaser and any users authorized by the Original Purchaser are hereby granted a nonexclusive, nontransferable license to use the Licensed Computer Program only in conjunction with the single Pump supplied by Manufacturer. The Licensed Computer Program is supplied only in machine-readable object code form and is based upon Manufacturer’s proprietary confidential information. No rights are granted under this license or otherwise to decompile, produce humanly readable copies of, reverse engineer, modify or create any derivative works based upon the Licensed Computer Program.
    3. All other terms and conditions of this Limited Warranty shall apply to the Licensed Computer Program.

      The Manufacturer disclaims responsibility for the suitability of the Pump for any particular medical treatment or for any medical complications resulting from the use of the Pump. The Manufacturer shall not be responsible for any incidental damages or consequential damages to property, loss of profits, or loss of use caused by any defect or malfunction of the Pump.

      This warranty gives the Original Purchaser specific legal rights, and the Original Purchaser may have other legal rights which may vary from state to state.

    Index

    A
    AC adapter
    accessory jack
    accuracy tests
    AC indicator light
    arrow keys
    B
    batteries, AA
      installing
    battery compartment
    battery contacts, cleaning
    battery, internal clock
    battery life
    biomed functions
      extra dose lockout
      morning dose lockout
      specifications
      upstream occlusion sensor on/off
    biomed functions code
    C
    cassette latch
    cleaning pump
    continuous rate
      programming
    D
    downstream occlusion sensor
    E
    ECG equipment, interference with
    electromagnetic emissions and immunity declarations
    extra dose
      Lockout
      programming
      starting
      stopping
    extra dose key
    G
    given
      clearing
    K
    keypad, keys
    L
    latch, cassette
    lock level
      changing
    lock level code
    M
    magnetic resonance imaging
    main screen
    medication cassette reservoir
      attaching
      removing
    morning dose
      Lockout
      starting
      stopping
    P
    power jack
    power-up
    priming
    programming
    programming, general
    programming screens
    R
    radiation, exposure to
    reservoir volume
      programming
      resetting
    S
    safety features
      hardware
      software
    security codes
      biomed functions code
      lock level code
    service due
    software version
    specifications
      biomed functions
      delivery
      general
    standards
    starting pump
    stopping pump
    symbols
    system definition
    T
    turning pump on/off
    U
    ultrasound, vii
    upstream occlusion sensor
    W
    warnings and cautions
    warranty

    Appendix A – Pump Programming Quick Reference for Healthcare Providers

    This quick reference provides for step-by-step directions for several of the common pump programming tasks performed with the CADD-Legacy® 1400 pump. Additional pump information including warnings, cautions and more information on pump operations is located in the referenced sections of the pump Operator’s Manual. Please refer to the full prescribing information for DUOPA (carbidopa and levodopa) enteral suspension for indications and usage, contraindications, warnings, precautions, and adverse reactions.

    Begin programming the pump by:

    • Attaching a medication cassette reservoir
    • Turning on the pump

    For instruction on attaching a medication cassette reservoir, see Section 2, Pump Setup and Programming.

    You will need the following items to complete these steps:

    • Pump
    • Medication cassette reservoir

    Changing to Lock Level 0 (LL0)

    Lock level 0 (LL0) allows the health care provider to adjust settings so they are appropriate for the patient. For more information on lock levels descriptions, see Section 1, General Description. For more information on changing the lock level, see Section 2, Pump Setup and Programming.

    **Text Omitted**

    Pump Programming Settings

    Program the pump settings to customize the medication delivery inputs for the patient. For more information see Section 2, Pump Setup and Programming.

    NOTE: Ensure that the pump is in lock level 0 (LL0) andstopped appears on the screen.

    1. Press
      next-36
      Check for
      rvnotinuse
      on the screen.

      NOTE: Not in Use is the default setting for the reservoir volume. The reservoir volume feature is not required for use, but is available at provider discretion.

    2. Press
      next 36a
      again. Check for
      contrate
      on the screen.
    3. Press
      up button-17
      or
      down 0c
      to select the desired continuous rate.
    4. Press
      enter clear-25

      Pump Status: The continuous rate is now set.

    5. Press
      next 0u
      Check for
      extradoseml
      on the screen.
    6. Press
      up button 0f
      or
      down 0b
      to select the extra dose amount.
    7. Press
      enter clear-25a

      Pump Status: The extra dose amount is now set.

    8. Press
      next-button-0w
      Check for
      given
      on the screen
    9. Press
      enter clear 0g
      if you wish to clear the amount given.
    10. Press
      next-0u

    NOTE: To change a setting again, press NEXT until the appropriate screen appears. Press up button 0g or down 0ato adjust the setting, then press enter clear 0hto confirm.

    Changing Lockout Times

    Program the dose lockout times to customize medication delivery inputs for each patient. Lockout times will determine how often a patient can deliver a morning dose and an extra dose. These values should be determined during titration. For more information on DUOPA titration, refer to the full prescribing information for DUOPA (carbidopa and levodopa) enteral suspension.

    The biomed functions allow the health care provider access to the extra dose lockout and morning dose lockout settings. For more information about biomed functions, see Section 4, Biomed Functions.

    NOTE:

    • Ensure that the pump is in lock level 0 (LL0) and
      stopped
      is on the screen.
    • When entering a new lockout value, any lockout time previously in effect will be cleared.

    **Text Omitted**

    Programming the Morning Dose

    Program the morning dose to customize medication delivery for the patient. For more information, see Section 2, Pump Setup and Programming.

    CAUTION: Review programming screens when complete to make sure desired programming has been entered. Check to make sure unintended changes were not made to the morning dose, continuous rate, or extra dose volume. If unintended changes were made, go to the appropriate screen and program the desired value.
    1. The pump must be running with a cassette attached and in LL0 or LL1. Start the pump, if necessary and confirm the lock level settings.

      NOTE: In LL0, programming in the full range is possible. In LL1, you can program up to the LL0 value.

    2. Press
      morn dose-130
      morningdose
      should appear on the screen.
    3. Press
      up button 0h
      or
      down-button-18a
      to select the desired morning dose volume.
    4. Press
      enter clear 0i
      to store the morning dose volume.

    Setting the Lock Level

    For patient use, the pump must be set to lock level 2 (LL2) or lock level 1 (LL1). For more information on lock levels descriptions, see Section 1, General Description. For more information on changing the lock level, see Section 2, Pump Setup and Programming.

    **Text Omitted**

    Manufacturer:
    Smiths Medical ASD, Inc.
    1265 Grey Fox Road
    St. Paul, MN 55112 USA
    Tel: 1 800 258 5361 (USA), +1 614 210 7300
    www.smiths-medical.com

    rx only-2

    CADD, CADD-Legacy, and Smiths Medical design mark are trademarks of Smiths Medical. The symbol ® indicates the trademark is registered in the U.S. Patent and Trademark Office and certain other ­countries. All other names and marks mentioned are the trade names, trademarks or service marks of their respective owners.

    © 2015 Smiths Medical. All rights reserved.

    2015-01
    40-6756-01C

    smithslogo

    PRODUCT PHOTO

    NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

    The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected over dosage, the drug's identity should be verified by chemical analysis.

    Image from Drug Label Content